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Mobile group II introns consist of a self-splicing RNA molecule and an intron- 
encoded protein with reverse transcriptase activity that function together in an RNP and 
catalyze the insertion of the intron into specific DNA target sites by a process known as 
retrohoming.  The mechanism of insertion requires the intron RNA to bind and reverse 
splice into one strand of the DNA target site, while the intron-associated protein cleaves 
the opposite DNA strand and reverse transcribes the intron RNA.  DNA target site 
recognition and binding are dependent upon base pairing between the intron RNA and the 
target DNA molecule.  By modifying the recognition sequences in the intron RNA, group 
II introns can be engineered to insert into virtually any desired target DNA.  Based on 
this technology, a novel class of commercially available group II intron-based gene 
targeting vectors, called targetrons, has been developed.  Targetrons have been used 
successfully for gene targeting in a broad range of bacteria. Previously, our laboratory 
demonstrated that group II introns retain controllable retrohoming activity in mammalian 
 vii 
cells, albeit with very low targeting efficiency.  However, the gene targeting capability of 
group II introns is not limited to direct insertion of the intron.  Group II introns can also 
create double-strand breaks that stimulate homologous recombination.  By virtue of these 
attributes, mobile group II introns offer great promise for applications in genetic 
engineering, functional genomics and gene therapy.  Here I present the results of 
experiments in which I tested group II introns for gene targeting activities in eukaryotic 
cells.  First, I demonstrated that group II introns injected into zebrafish (Danio rerio) 
embryos retain in vivo plasmid targeting activity that is enhanced by the addition of 
magnesium chloride and deoxynucleotides.  I also verified that similar in vivo targeting 
activity is retained in Drosophila melanogaster embryos.  Further, I describe repeated 
experiments in zebrafish embryos designed to target the zebrafish genome with 
inconclusive results.  Group II introns were also delivered to cultured human cells for 
genome targeting.  Here I present promising evidence for the ability of group II introns to 
stimulate homologous recombination between an exogenously introduced donor DNA 
molecule and the chromosome.  The donor DNA was delivered either as a linearized 
double-stranded plasmid by electroporation or as a single stranded genome of a 
recombinant adeno-associated virus (AAV).  In both cases, cells receiving both the group 
II intron RNP and the donor DNA showed more efficient integration of the donor DNA 
than introduction of the donor DNA alone.  The studies presented here provide insight 
into the potential of using group II introns for future applications in gene targeting in 
eukaryotes.  
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CHAPTER 1: INTRODUCTION 
 Group II introns are ribozymes that catalyze their own splicing reaction from 
precursor RNAs and are in some cases mobile elements that use their ribozyme activity to 
insert into DNA (Pyle & Lambowitz 2006).  First discovered in the mitochondrial and 
chloroplast genomes of lower eukaryotes and higher plants, mobile group II introns 
consist of a highly structured catalytic RNA and, a multifunctional, intron-encoded 
protein (IEP) (Lambowitz & Zimmerly 2004).  Group II introns have also been found in 
bacterial genomes, as well as in archa (Rest & Mindell 2003). Although only one third of 
organellar group II introns contain ORFs for IEPs, nearly all bacterial and archael group 
II introns do so (Michel & Lang 1985, Toor et al. 2001). 
 Sequence comparison showed that group II intron IEPs are homologous to reverse 
transcriptases (RTs), which are encoded by retroviruses, LTR- and non-LTR-containing 
retrotransposons, and telomerase (Michel & Lang 1985), and biochemical studies showed 
that they have RT activity (Kennell et al. 1993). Group II intron RTs typically contain 
four conserved domains: RT, which corresponds to the fingers and palm regions of 
retroviral RTs; X, which corresponds to the RT thumb; D, DNA binding; and En, DNA 
endonuclease (Blocker et al. 2004). The latter two domains contribute to interactions with 
DNA target sites during intron mobility (San Filippo and Lambowitz 2002). 
 The ribozyme activity of the intron RNA combined with the multifunctional IEP 
allows group II introns to act as mobile retroelements capable of inserting into DNA 
targets (Lambowitz & Zimmerly 2004).  The mechanisms of group II intron retromobility 
and the rules for DNA target recognition have been studied extensively leading to the 
! #!
development of retargetable introns that are capable of inserting into essentially any 
desired DNA target (Perutka et al. 2004).  Sigma-Aldrich Corporation has 
commercialized group II intron gene targeting technology for prokaryotes under the 
product name of TargeTron
®
.  Targetrons have been used in a variety of prokaryotes for 
gene targeting with impressive levels of success (Frazier et al. 2003, Chen et al. 2005, 
Yao et al. 2006, Heap et al. 2007, Shao et al. 2007, Yao & Lambowitz 2007, Rodriguez et 
al. 2008).  The broad usage of targetrons in prokaryotes raises the question of whether 
group II introns can be used as a controllable gene-targeting vector for eukaryotes.  Here 
I describe our attempts to harness the power of group II introns for uses in various 
metazoan systems.      
1.1 Distribution and Classification of Group II Introns 
 Group II introns and their distribution throughout the biological world suggest a 
complex evolutionary history of DNA mobility, genetic transfer and evolutionary 
conservation, divergence and degeneration.  Group II introns were originally discovered 
in the mitochondrial DNA (mtDNA) of lower eukaryotes, including yeast, and the 
chloroplast DNA (cpDNA) of alga and higher plants, where they are generally inserted 
within coding sequences (Lambowitz & Belfort 1993).  Later, group II introns were 
found to be relatively common among gram-positive and gram-negative bacteria (Dai & 
Zimmerly 2003, Toor et al. 2001).  In bacteria, group II introns are frequently inserted 
into intergenic sequences, mobile DNAs or plasmids, which may have promoted their 
dispersal throughout the prokaryotic world (Dai & Zimmerly 2002, Ichiyanagi et al. 
2003).  More recently, group II introns have been identified in archaeal genomes, albeit 
! $!
more rarely than in bacteria (Toro 2003, Dai & Zimmerly 2002, Galagan et al. 2002, 
Deppenmeier et al. 2002). 
 The spread of group II introns is at least partly due to their ability to function as 
retroelements through the combined activity of the intron RNA and IEP.  Extensive 
analysis of the phylogenetic relationships between group II IEPs identified eight clades, 
designated mitochondrial-like, chloroplast-like 1 and 2 and bacterial A-E (Toro et al. 
2002, Zimmerly et al. 2001).  Each lineage of IEP is associated with a defined RNA 
structural subclass.  Group II intron RNAs are divided into three major subgroups (IIA, 
IIB, IIC) based on RNA structural variations (Michel et al. 1989, Michel & Ferat 1995, 
Qin & Pyle 1998, Toor et al. 2001).  The most distinctive RNA structural components 
that define the subgroups are responsible for alignment of the splice site and the 
recognition of intron and exon sequences for splicing.  For group IIA introns, recognition 
of the exons by the intron is done by the exon-binding sequences (EBS1, EBS2), which 
base pair with intron-binding sites (IBS1, IBS2) located in the 5’ exon, and !, which is 
adjacent to the EBS1 sequence and pairs with !’ corresponding to the first one or two 
nucleotides of the 3’ exon (Michel et al. 1989).  Group IIB and IIC introns have a 
different exon binding sequence (EBS3) in domain I that pairs with at least the first 
nucleotide in the 3’ exon, now referred to as IBS3 (Costa et al. 2000).  Groups IIA and 
IIB are further subdivided into subclasses: A1 and A2, B1 and B2 based on additional 
sequence variations (Michel et al. 1989, Michel & Ferat 1995, Qin & Pyle 1998). 
 Despite the widespread presence of group II introns in organelles and prokaryotes, 
only a few group II introns have been identified in the mitochondrial genes of animals, 
! %!
each from early diverging metazoan lineages including the annelid worm, Nephtys, and 
the placozoan, Trichoplax adhaerens (Valles et al. 2008, Dellaporta et al. 2006).  Group 
II introns have yet to be identified in any metazoan animal organellar or nuclear genome.  
However, due to significant similarities in splicing mechanisms and splicing products, 
group II introns are believed to be the evolutionary predecessors of the spliceosomal 
introns of animals and other eukaryotes (Cech 1986).  An indication that group II introns 
might have given rise to spliceosomal introns is the finding that some group II introns in 
plant mitochondria and chloroplasts are transcribed in two or three segments that re-
associate via tertiary interactions and carry out “trans-splicing” (Bonen 1993).  The 
ability of such independently transcribed segments to functionally reassociate supports 
the hypothesis that group II intron domains may have evolved into the snRNAs that 
reassociate to form the spliceosome (Sharp 1985). 
 One explanation for the evolution of group II introns into spliceosomal introns is 
that shortly after the origin of the mitochondrion via endosymbiotic absorption of an "-
proteo-bacterium and the chloroplast from cyanobacteria, group II introns escaped these 
organelles and invaded the host cell chromosomes, subsequently spreading throughout 
the genome (Palmer & Logsdon 1991, Cavalier-Smith 1991, Martin & Koonin 2006). 
Martin and Koonin (2006) expanded upon this hypothesis by suggesting that the spread 
of group II introns and their mutational decay into spliceosomal introns created a strong 
selective pressure for independent compartmentalization of the splicing and translation 
pathways giving rise to the need for the nucleus-cytosol separation.  The absence of 
functional group II introns in eukaryotic genomes suggests that eukaryotes have avoided 
! &!
recent group II intron invasions since the emergence of spliceosomal introns, but does not 
preclude the possibility that group II introns could be artificially introduced into 
eukaryotes for technological purposes. 
1.2 RNA Structure and Self-splicing of Group II Introns 
 Group II intron RNAs catalyze splicing by folding into highly conserved secondary 
and tertiary structures that form an active site, just as in a protein enzyme (Pyle & 
Lambowitz 2006). Despite having little primary sequence conservation, all group II 
introns exhibit a conserved secondary structure that consists of a central wheel with six 
double helical domains (DI-DVI) radiating outward (Figure 1.1).  These six domains fold 
to form a tertiary structure that catalyzes two magnesium-dependent transesterification 
reactions; 1) the bulged A residue in DIV creates the lariat structure by reacting with the 
first nucleotide of the intron to form a 2’-5’ phosphodiester linkage and releasing the 5’ 
exon, 2) the 3’ hydroxyl of the free 5’ exon attacks the phosphodiester bond at the 3’ 
splice site, thereby ligating the exons (Figure 1.2).  The products of the splicing reactions 
are ligated exons and an excised intron lariat (Peebles et al. 1986, Schmelzer & 
Schweyen 1986, van der Veen et al. 1986).   
 An alternative-splicing pathway has also been observed in which a water molecule 
catalyzes the hydrolysis of the 5’ splice site.  The product of this reaction, a linear instead 
of a lariat intron, was shown to occur in self-splicing reactions under non-physiological 
conditions (Zhuang et al. 2009, Roitzsch & Pyle 2009, Pyle et al. 2006) (Figure 1.2).  
Branch point mutants, missing the bulged A residue from DVI, of the yeast mitochondrial 
(mt) group II intron aI5# can splice in vivo to form the linear intron (Podar et al. 1998).  
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While other introns have been observed to undergo splicing in vivo by mechanisms that 
yield linear intron RNA, it is currently thought the most common mechanism for group II 
intron splicing is the lariat-forming pathway (Podar et al. 1998, Vogel and Börner 2002). 
 The minimal catalytic core for the group II intron splicing reaction consists of DI 
and DV (Michel et al. 1989).  DI contains exon-binding sequences (EBS1 and EBS2) that 
form classical Watson-Crick base pairs with specific nucleotides in the exons (intron 
binding sequences, IBS1 and IBS2) (Figure 1.3) (Jacquier & Michel 1987, Michel & 
Jacquier 1987).  Base pairing interactions between the intron and 5’ exon are essential for 
RNA splicing, but differ somewhat for the different intron classes.  DI also contains 
sequences (! or EBS3) that contribute to splicing by base pairing to the flanking 3’ exon 
sequence (Michel & Ferat 1995; Costa et al. 2000).  DV, the most conserved hairpin 
sequence among group II introns, docks with DI to form essential active-site structures 
(Qin & Pyle 1998).   
 While they do not participate in catalysis of the splicing reaction, DII and DIII 
contribute to RNA folding and catalytic efficiency.  Splicing reactions can proceed under 
high salt conditions when DII and DIII are removed, but the efficiency of the second step 
of the splicing reaction is significantly reduced (Fedorova et al. 2003, Michel & Ferat 
1995).  DIV is the least conserved domain of group II introns and is largely dispensable 
for ribozyme activity. However, DIV is significant because it contains the ORF sequence 




1.3 Group II Intron-Encoded Proteins and Protein-Assisted Splicing 
 Group II intron IEPs are required for both RNA splicing and intron mobility 
(Michel & Ferat 1995).  Whereas some group II introns are able to self-splice in vitro, 
this self-splicing generally requires non-physiological conditions, such as high salt, Mg2+, 
and/or temperature, and does not occur efficiently. The ribozyme and the IEP have 
coevolved to such a degree that the protein is required in vivo to help the intron RNA fold 
into a catalytically active structure (Michel & Ferat, 1995, Lambowitz & Zimmerly 2004, 
Lambowitz & Belfort, 1993, Zimmerly et al. 1999).  More importantly for dispersion of 
group II introns, following splicing the protein remains associated with the excised intron 
RNA as a ribonucleoprotein, RNP, and participates in intron mobility reactions 
(Lambowitz & Zimmerly 2004).   
 Group II intron IEPs have sequence homology to the RTs of retroviruses and 
retrotransposable elements (Michel & Lang, 1985).  One hypothesis for the presence of 
RTs in group II introns posits the insertion of a pre-existing RT ORF, such as a retron 
RT, into a self-splicing RNA to form a new type of retrotransposable element 
(Lambowitz & Belfort, 1993, Wank et al. 1999).  Since the similarity to reverse 
transcriptases was identified, additional domains have been discovered in the coding 
sequences of group II intron IEPs, including X, thumb/maturase; D, DNA binding, and 
En, DNA endonuclease (Figure 1.4).  Each of these domains contributes to the activities 
of the protein.   
 The RT and X/thumb domains, which share conserved sequences with HIV-1 RT, 
bind specifically to the intron RNA and stabilize the catalytically active RNA structure 
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that is required for RNA splicing (Figure 1.4) (Saldanha et al. 1999, Wank et al. 1999, 
Matsuura et al. 2001, Noah & Lambowitz 2003, Blocker et al. 2005).  RNA splicing does 
not require either the D or En domains.  In fact, more than half of bacterial IEPs lack an 
endouclease domain (En) and many are also missing a readily identifiable DNA-binding 
domain (D) (Martinez-Abarca et al. 2000, Zimmerly et al. 2001, Belfort 2003, Toro 2003, 
Lambowitz & Zimmerly 2004).  Analysis of the En and D domains of LtrA, revealed that 
the two domains may have been acquired together from an endonuclease VII-type protein 
(San Filippo & Lambowitz 2002).  Certain lineages of group II introns appear to have lost 
the D and En domains because they were deleterious to the host (San Filippo & 
Lambowitz 2002).  When present, however, the En and D domains, in conjunction with 
the RT domain, provide critical enzymatic activities that contribute to the mobility of 
group II introns. 
1.4 Mechanism of Group II Intron Mobility 
 The distribution of group II introns throughout the biological world is dependent 
upon the ability of the introns to mobilize in permissive cellular environments.  The 
principal means by which group II introns spread are called retrohoming and 
retrotransposition.  Retrohoming is the process by which the intron RNA inserts into a 
specific DNA target sequence, often the ligated exon junction of an intronless allele, 
referred to as the homing site. Retrotransposition occurs at a lower frequency and 
involves insertion into a non-cognate DNA target site that resembles the normal homing 
site.   The latter pathway serves as a major contributor to distribution of group II introns 
into novel DNA sites through ectopic integrations (Toro et al. 2007, Pyle & Lambowitz 
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2006, Lambowitz & Zimmerly 2004).  Both retrohoming and retrotransposition use 
essentially the same mechanism for integration of the intron into DNA sites.   
 The mechanism for integration of the group II intron into a DNA target site is 
referred to as target DNA-primed reverse transcription (TPRT) and is analogous in some 
respects to the TPRT mechanism used by non-LTR retrotransposons (Zimmerly et al. 
1995, Eickbush 1999).  The process of target site integration is dependent upon the RNA 
and the IEP, which remain bound together following the forward splicing reaction to 
form a ribonucleoprotein complex (RNP).  In order to initiate the mobility pathway, the 
RNP must first identify a DNA target site.  Group II intron RNPs recognize relatively 
long (30-35) stretches of nucleotides via DNA-binding regions of the IEP and base-
pairing interactions between the intron RNA and the DNA target site (Guo et al 1997, 
Guo et al. 2000, Mohr et al. 2000, Singh & Lambowitz 2001).  For the Ll.LtrB intron, the 
RNA base pairs with the DNA target site from position -12 to +2.   The IEP recognizes a 
small number of nucleotide residues in the regions flanking the RNA-DNA base pairs. 
Following recognition of the target site, the intron RNA reverse splices into the top strand 
of the DNA (Lambowitz & Zimmerly 2004, Lambowitz & Pyle 2006).  Like some non-
LTR retrotransposons, group II intron RNPs that have an intact En domain can generate a 
specific cleavage at their target sites (Malik & Eickbush 1999, San Filippo & Lambowitz 
2002, Lambowitz & Zimmerly 2004).  Nevertheless, the Ll.ltrB intron is able to utilize 
both En-dependent and En-independent means of mobilization (Zhong & Lambowitz 
2003, Coros et al 2005).  When employing the En-dependent mechanism, the En domain 
of the IEP, which contains an H-N-H DNA endonuclease motif, cleaves the bottom 
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strand of the DNA target site between nucleotides +9 and +10 (San Filippo & Lambowitz 
2002).  Cleavage of the bottom strand creates a free 3’ hydroxyl group that functions as 
the primer for cDNA synthesis of the intron RNA by the RT domain of the IEP (Eskes et 
al. 1997, Cousineau et al. 1998, Eskes et al. 2000).  In the En-independent mechanism, 
the target site recognition and reverse splicing reaction are essentially the same but a 
nascent strand at a DNA replication fork is used to prime reverse transcription of the 
inserted intron RNA (Zhong & Lambowitz 2003).  In both cases, once the full-length 
cDNA has been generated, subsequent repair of the cDNA junction and removal and 
replacement of the intron RNA are performed by host enzymes (Cousineau et al. 1998, 
Smith et al. 2005, Eskes et al. 1997, Eskes et al. 2000).   
 While the above mentioned pathways are specific to lariat group II introns, a novel 
mobility pathway for linear group II introns has recently been proposed (Zhuang et al. 
2009, Roitzsch & Pyle 2009).  Here, it was shown that linear group II introns can carry 
out the first step of the mobility process by reverse splicing into DNA targets followed by 
reverse transcription of the intron RNA (Mastroianni et al. 2008).  The resulting cDNA 
was integrated into the recipient DNA by host DNA repair pathways (Mastroianni et al. 
2008, Zhuang et al. 2009).  These three mobility pathways offer a broad range of 
potential applications for group II introns in gene targeting.  
1.5 Use of Group II Introns for Gene Targeting and Genetic Engineering in 
Prokaryotes 
 
 Since intron mobility was originally demonstrated using the yeast and K. lactis 
coxI-I1 introns, a great deal of work has been done to understand the processes involved 
(Meunier et al. 1990, Skelly et al. 1991).  Once the mechanisms for recognizing the DNA 
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target site and integration were clearly defined, a new era of group II intron engineering 
emerged.  The earliest attempts at engineering group II introns were designed to alter 
their targeting specificity by modifying the RNA and DNA base-pairing interactions of 
the yeast mitochondrial aI1 and aI2 and the Lactococcus lactis, Ll.LtrB intron RNAs 
(Guo et al. 1997, Eskes et al. 1997, Matsuura et al. 1997).  The greatest success was 
achieved using Ll.LtrB intron due to the development of an efficient E. coli expression 
system for this intron (Matsuura et al. 1997), and it has become the best characterized and 
most widely used group II intron for genetic engineering experiments.   
 Shortly after the first experiments involving modification of base-pairing 
interactions were performed, detailed DNA target-site recognition rules were established 
for the Ll.LtrB intron (Mohr et al. 2000, Guo et al. 2000, Zhong et al. 2003).  It was 
determined that group II introns could be retargeted to insert efficiently into desired DNA 
targets simply by modifying the intron RNA (Guo et al. 2000).  A randomized intron 
library containing a retrotransposition-activated genetic marker (RAM) was used to 
generate a database of introns and target sites along with their integration efficiencies 
(Zhong et al. 2003).  The information gathered in these studies was used to construct an 
algorithm that designs introns to target a given gene with high efficiency and a new 
prokaryotic gene targeting technology was born (Perutka et al. 2004).  This technology 
allowed for development of programmable bacterial gene targeting vectors, called 
“targetrons.”  Targetron technology has been used to successfully disrupt and deliver 
genes in a variety of medically and commercially relevant strains of gram-positive and 
gram-negative bacteria (Frazier et al. 2003, Shao et al. 2007).  By introducing retargeted 
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Ll.LtrB introns into a strain of bacteria via a donor plasmid expressing the intron and 
IEP, both conditional and non-conditional gene disruptions can be generated, depending 
on the orientation of the intron insertion and expression of the IEP (Guo et al. 2000, 
Karberg et al. 2001, Frazier et al. 2003, Yao et al. 2006).  Clearly, group II introns 
provide an impressive set of tools for prokaryotic genetic engineering.  Similar success in 
eukaryotes would make obsolete many of the current eukaryotic genetic engineering 
tools.  
1.6 Current Methods of Gene Targeting and Genetic Engineering in Eukaryotes 
 
In many cases, current eukaryotic gene-targeting methods are organism-specific 
and are often limited by inherent disadvantages.  For the mammalian model organism, the 
mouse, a commonly used gene silencing process called RNA interference relies on short 
dsRNA molecules called siRNAs (Paddison et al. 2002).  A cytoplasmic ribonuclease 
called dicer processes the siRNAs from longer precursors.  The antisense strand of the 
siRNA remains associated as the effector for the RNA-induced silencing complex (RISC) 
to recognize and cleave a complementary messenger RNA, targeting it for degradation 
(Meister et al. 2004).  Application of siRNAs has been effective, in many respects, for 
determining the role of specific genes in the mouse genome, but interpretation of siRNA 
studies are complicated by the fact that this method creates knock-downs, not knock-outs 
(Mittal 2004).  Also, the siRNA oligos used in these experiments are unstable and must 
be constantly replenished for long-lasting gene silencing (Sandy et al. 2005).  High 
intracellular concentrations of siRNAs can be maintained by expressing them from stably 
transfected plasmids or from integrated viral vectors.  These types of expression 
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constructs obviously run the risk of integrating uncontrollably into the genome with 
unintended consequences.  In recent years, the need to develop efficient ways of 
designing, identifying and delivering effective siRNAs has also become more important.  
Until these complications are addressed, the full impact of siRNA technology will remain 
at large. 
While siRNAs are widely used in the mouse, the most common method of gene 
targeting is the site-specific integration of exogenous DNA by homologous 
recombination (HR).  The advantage of HR technology over siRNAs is that HR creates 
germ-line mutations that are maintainable in cell culture and transferable to animals.  
Generally, this involves the introduction into cultured mouse stem cells of foreign 
double-stranded DNA that is engineered to contain regions of sequence homology to the 
chromosome (Wang & Zhou 2003).  The donor DNA molecule used for HR-based gene 
targeting traditionally includes a selectable marker inserted in such a way as to disrupt the 
target gene upon integration (Figure 1.5).  Delivery of the donor DNA to the nucleus by 
microinjection, electroporation or lipid-based transfection triggers the homologous 
recombination machinery to align the regions of homology to the chromosome and 
incorporate the exogenous DNA into the target site.  Cells containing targeting events are 
isolated using selectable markers expressed from the integrated donor DNA.  To further 
aid in the selection process, donor DNAs can be designed to express negative selection 
markers from non-integrated or randomly integrated copies.  Because HR is a highly 
inefficient process (10-6 integrations/cell), the screening methods can be labor-intensive 
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and cost-prohibitive.  Further, the need to create and introduce transgenic material into 
the cell always leads to concerns about off-target effects.  
More recently the use of adeno-associated virus for delivery of the donor DNA in 
HR-based gene targeting has become an attractive alternative to double-stranded plasmid 
DNA.  The genome of AAV, a human parvovirus with broad cellular tropism, is 
encapsidated as a single-stranded DNA.  Recombinant AAV (rAAV) can be engineered 
by exchanging the viral genes located between the inverted terminal repeat sequences 
(ITRs) with up to 4.7 kb of target-derived replacement DNA (Porteus et al. 2003, Russell 
& Hirata 1998, Samulski et al. 1989).  rAAV gene targeting vectors provide gene 
disruptions 3-4 orders of magnitude more efficiently than those achieved by conventional 
targeting approaches using double-stranded DNA (Yan et al. 2009).  Although the 
mechanism of rAAV homologous recombination is poorly understood, it is assumed that 
it occurs through processes similar to conventional gene targeting.  The advantages that 
rAAV has over other targeting strategies may reside in the single stranded genome of the 
virus, which is flanked by the highly ordered secondary structure of the ITRs.  These 
structures may be highly efficient at binding DNA repair enzymes, thereby more easily 
integrating into the genome (Yan et al. 2009).  While the highly efficient gene targeting 
of rAAV is attractive, the need for extremely high MOIs to achieve these results limits 
the use of rAAV to non-therapeutic purposes (Porteus et al. 2003).  Further, the potential 
for random integration is currently too high at even low MOIs.  Clearly, there is a need 
for an improved gene targeting strategy for mice.  Similar problems exist for gene 
targeting strategies in other model organisms, like zebrafish. 
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Unlike in mouse gene targeting experiments, which are most often carried out in 
cell culture, injecting the gene targeting effectors directly into early stage embryos is the 
usual protocol for zebrafish gene targeting.  Techniques that are commonly used in 
mouse, such as homologous recombination and RNAi, are not routinely available for 
zebrafish (Deiters & Yoder 2006).  First, homologous recombination is not the preferred 
mechanism for integration of exogenous DNA during embryonic development in 
zebrafish.  Although the cellular machinery for homologous repair is present in zebrafish 
embryos, double-strand breaks tend to be predominantly repaired by DNA end-joining 
mechanisms, so exogenously introduced linear DNAs tend to integrate randomly into the 
genome (Hagmann et al. 1998).  Secondly, the effective concentration necessary for 
traditional RNAi-based targeting, in mouse, is toxic to zebrafish embryos.  A commonly 
used and reasonably successful technique for gene disruption in zebrafish relies on the 
mutagenic capacity of retroviruses (Amsterdam et al. 1999).  Like the advances made in 
Drosophila melanogaster using P elements (Cooley et al. 1988), insertional mutagenesis 
using pseudo-typed retroviruses in zebrafish speeds the process of cloning mutant genes 
significantly, compared to chemical mutagenesis (Amsterdam et al. 1999).  While some 
labs have been very successful using insertional mutagenesis in zebrafish, the process 
requires large-scale screening, is not target-specific, and occasionally results in secondary 
mutations that induce additional phenotypes (Iversen & Newbry 2005).     
The most commonly used method of studying gene function in zebrafish utilizes 
modified gene-targeted RNA oligonucleotides, called morpholinos (Nasevicius & Ekker 
2000).  The term morpholino refers to phosphoramidite morpholino oligomers that have 
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an advantage over traditional antisense RNA oligos because they are inert and do not 
elicit toxic effects in zebrafish cells.  However, as is true for siRNAs in mice, the 
morpholino oligos do not result in complete knockouts of gene function, but rather lead 
to a knockdown of gene expression.  Further, a common criticism of morpholino gene 
targeting is that it is not 100% effective (Iversen & Newbry 2005).  In fact, morpholino 
gene targeting is unsuccessful, as often as, 26% of the time (Iversen & Newbry 2005).  
The non-specific effects associated with morpholinos have not been fully characterized 
and there is little impact on genes expressed in embryos older than two days (Eisen & 
Smith 2008, Iversen & Newbry 2005).    
A promising method of gene targeting, known as tilling (Targeting Induced Local 
Lesions in Genomes), recently emerged as the next promising tool for studying zebrafish 
genetics.  Tilling is a hybrid of reverse and classical genetic approaches whereby 
genomic DNA from a large library of ENU-mutagenized zebrafish is screened for rare 
mutations in genes of interest.  It is the screening method that makes this technology 
more effective than traditional genetics because mutations in specific genes can be 
detected directly in the genomic DNA of heterozygous or homozygous individuals, 
irrespective of any phenotypes they may cause (Moens et al. 2008).  Unfortunately, 
because this is a PCR-based screening method that relies on rare chemical-induced 
mutations, amplicons that contain a high frequency of naturally occurring single 
nucleotide polymorphisms (SNPs) can complicate the screening process (Barkley & 
Wang 2008).  The TILLING method also requires a great deal of experience to develop 
the ability to distinguish false positives and false negatives from actual mutants.  Further, 
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it can be labor intensive when not using robotic equipment to process the large numbers 
of samples involved and, thusly, the recommended equipment for TILLING is often cost 
prohibitive for smaller labs.   
A gene targeting technique that offers promise for uses in several different model 
organisms capitalizes on the advances made in the field of chimeric restriction enzymes, 
specifically zinc-finger nucleases (ZFN) (Porteus & Carroll 2005).  Here, a non-specific 
restriction endonuclease (FokI) domain is fused to a DNA binding motif, in this case a 
zinc-finger DNA binding domain (Chandrasegaran & Smith 1999).  Since the recognition 
specificity of zinc fingers can be manipulated experimentally, the chimeric nuclease can 
be engineered to recognize specific sequences within the genome.  Using these re-
targetable endonucleases, researchers can take advantage of various cellular repair 
mechanisms to carry out genome engineering.   
By introducing a double-strand break at a specific target site, one can expect 
multiple pathways to be involved in repairing, editing or mutating the genome.  For 
example, repair by the inherently mutagenic non-homologous end-joining (NHEJ) 
pathway can disrupt a gene that has suffered a double-strand break, either naturally or 
artificially (van Gent et al. 2001).  Additionally, the introduction of a double-strand break 
at a specific site in a gene can stimulate the homologous recombination pathway, which 
naturally repairs DSBs by using the undamaged sister chromatid as a template (van Gent 
et al. 2001).  Alternatively, the introduction of an exogenous DNA containing sufficient 
homology to the region of the double-strand break can co-opt the host cell’s DSB repair 
pathway to incorporate the foreign DNA at the cleavage site.  In fact, ZFNs have been 
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shown to stimulate gene targeting by directing the homologous recombination machinery 
to site-specifically integrate exogenous DNAs (Cathomen & Joung 2008, Porteus & 
Carroll 2005).  The combination of artificially introduced double-strand breaks by ZFNs 
with HR-based incorporation of donor DNA molecules increases targeting efficiencies 
from 1 in 105 cells to as much as 39% in certain cell lines (Cathomen & Joung 2008).  
Thusly, the use of ZFNs for gene targeting has been extended to a variety of model 
organisms including mouse, Xenopus, zebrafish and Drosophila. 
As powerful as the zinc-finger methodology appears to be, it has the disadvantage 
of requiring protein engineering in order to retarget the nuclease to new target sites.  This 
is a notable drawback because it limits the rate and extent to which these enzymes can be 
modified.  Further, each of the two existing methods of engineering ZFN has inherent 
problems.  Modular assembly, the joining together of single zinc fingers with pre-
characterized specificities, has an efficacy rate for making functional ZFN pairs that is 
less than 6% and can yield ZFNs with low activities and high toxicities (Ramirez et al. 
2008, Bae et al. 2003, Beerli & Barbas 2002, Liu et al. 2002, Mandell & Barbas 2006, 
Segal et al. 2003).  Combinatorial selection-based methods that yield multifinger domains 
possessing high activities and low toxicities in human cells require construction and 
interrogation of large randomized libraries that make them intractable in most labs that 
lack the necessary expertise (Cornu et al. 2008, Pruett-Miller et al. 2008).  No matter the 
promise or widespread use of existing gene targeting technologies, it seems the 
disadvantages for each method leave room for new methods that address the existing 
limitations.  
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1.7 Promise and Significance of Eukaryotic Gene Targeting Using Group II Introns 
 
Clearly, a breakthrough in group II intron-based gene targeting technology for 
eukaryotes would be highly desirable.  Because we are proposing that group II introns 
possess many attractive characteristics regarding their potential applications in gene 
targeting and transgenesis, it seems necessary to compare their use to the most promising 
new gene targeting technologies currently being used today.  First, the ease of retargeting 
group II introns greatly exceeds the complicated methods for retargeting ZFNs and offers 
much more potential versatility over other gene targeting methods that rely on random 
events.  The mechanism of group II intron-based gene targeting also offers a wide range 
of biochemical activities that can be exploited for gene targeting.  First, the most obvious 
mode of gene disruption by group II introns is direct integration of the intron at the target 
site.  This provides the opportunity to create conditional and non-conditional gene knock-
outs.  As previously mentioned, integration of the intron in the sense strand of the coding 
sequence for the target gene allows for the addition of the IEP to facilitate removal of the 
intron from the transcript.  This results in an intact wild-type transcript that can undergo 
normal processing and translation.  Secondly, group II introns can create site-specific 
double-strand breaks (Karberg et al. 2001, Mastoianni et al. 2008).  By cutting the 
genome, group II introns can cause gene disruptions by either NHEJ or homologous 
recombination-dependent mechanisms.  Finally, group II introns offer the extraordinary 
ability to deliver cargo genes to a chosen target site via insertion of genetic information 
into DIV of the intron (Karberg et al. 2001, Frazier et al. 2003).  A vector, like the group 
II intron, that could deliver a transgene to a specific site in the genome would be an 
! #+!
invaluable tool.  Not only could this facilitate transgenic expression of a gene of interest 
from a chosen location, a gene could also simultaneously be disrupted. Significant 
success using group II introns in eukaryotes could pave the way for an entirely new 
approach to eukaryotic genetic engineering.    
1.8 Overview of Dissertation Research 
 This dissertation research has the major theme of advancing the use of group II 
introns toward gene targeting in eukaryotic cells.  I addressed two major subtopics: 1) 
examination of group II intron activity in eukaryotic embryos including zebrafish (Danio 
rerio) and Drosophila melanogaster (plasmid targeting and genome targeting in 
zebrafish, plasmid targeting in Drosophila) and 2) gene targeting in mammalian cells 
utilizing group II intron RNPs as site-specific endonucleases to stimulate homologous 
recombination of exogenously introduced donor DNA molecules (either a linearized 
double-stranded plasmid DNA or a recombinant single stranded adeno-asssociated virus, 
AAV, genome).  The results of this work will be summarized in two chapters followed by 


















Figure 1.1 Conserved Secondary Structure and Predicted Tertiary Interactions of the  
       Model Group IIA Intron, Ll.LtrB. 
 
The conserved secondary structure common to group II introns is composed of six 
double-helical domains (I-VI) radiating from a central wheel.  In this diagram, the 
structure of domain IV, which contains an ORF in some introns, is simplified to 
emphasize the overall structure of the intron. The EBS1, EBS2 and ! sequences are 
labeled in domain I and dotted lines reflect the base pairing interactions with the IBS1, 
IBS2 and !’ sequences in the 5’ and 3’ exons that are required for intron splicing.  A 
bulged A residue in DIV creates the lariat structure during the splicing reaction by 
reacting with the first nucleotide of the intron to form a 2’-5’ phosphodiester linkage.  
Adapted from Perutka et al., 2004. 
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Figure 1.2 Splicing Mechanisms for Group II Introns. 
 
The self-splicing reaction of group II introns can follow two different pathways.  
The two-step process can produce both linear and lariat introns.  The lariat pathway 
begins when the 2$-OH group of the bulged adenosine in DVI reacts with the first 
nucleotide of the intron to form a 2’-5’ phosphodiester bond releasing the 5’ exon.  The 
3’ hydroxyl then attacks the phosphodiester bond at the 3’ splice site to create the lariat 
form of the intron.  The alternative splicing pathway requires a water molecule to 
catalyze the hydrolysis of the 5’ splice site without forming a branched structure. The 3’ 
exon is removed from the intron in a manner similar to the lariat-forming pathway when 
the 5’ exon reacts with it to ligate the exons.  Adapted from Roitzsch & Pyle, 2009. 
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Figure 1.3 Base-Pairing Interactions Between the Intron and the Exons. 
 
(a) The exon-binding sequences (EBS1 and EBS2) in DI form classical Watson-
Crick base pairs with specific nucleotides in the exons (intron-binding sequences, IBS1 
and IBS2).  Base-pairing interactions are essential for RNA splicing.  DI also contains 
sequences (! and EBS3) that contribute to splicing by base pairing to the flanking 3’ exon 
sequence (Michel & Ferat, 1995, Costa et al., 2000).  Adapted from Perutka et al., 2004.  
(b) Base pairing interactions (EBS1/IBS1, EBS2/IBS2 and d/d’), lariat structure, 
insertion site (IS) for the intron RNA and the cleavage site (CS) at nucleotide +10 for the 


















Figure 1.4 Domains of the Group II Intron IEP and Comparison to HIV-1 RT. 
 
 The group II intron IEP contains several important domains including the RT 
region, which shares conserved sequence motifs RT1–RT7, found in the fingers and 
palm, with the HIV-1 RT.  The N-terminal RT domain of HIV-1 RT precedes the thumb, 
connection, and RNase H domains, while the RT domain of LtrA is located upstream of 
the thumb (X), DNA-binding (D), and DNA endonuclease (En) domains.  Adapted from 















Targeting vectors most commonly used for homologous recombination-based 
gene targeting in mouse ES cells include homology arms that flank a selectable marker.  
The marker disrupts the target gene upon insertion.  The targeting vector can be designed 
to express negative selection markers, as seen here (HSV-tk), to aid in the selection 



















CHAPTER 2: GROUP II INTRON-BASED GENE TARGETING IN 
EUKARYOTIC EMBRYOS 
 
In the field of eukaryotic molecular genetics, legions of scientists have sought to 
apply reverse genetics approaches to solve problems unanswered by classical genetic 
methods.  The strength of reverse genetics is the ability to disrupt a specific gene of 
interest without the need to screen through a vast number of random mutations.  Another 
method of studying genes by reverse genetics, known as transgenesis, allows researchers 
to learn about the function of a specific gene of interest by controlling the spatial and 
temporal expression of the gene.  By using transgenesis to control the expression of a 
particular gene or using gene targeting to disrupt the expression of a given gene, 
scientists have been able to gain knowledge that was previously indiscernible using basic 
genetic tools.  The combined benefits of gene targeting and transgenesis have influenced 
nearly every field of biological research from evolution and development to cancer 
biology.  Although a broad range of techniques have been developed for transgenesis and 
gene targeting in eukaryotes, each has distinct disadvantages that invite the development 
of improved technologies.  Today, one of the greatest challenges in molecular genetics is 
the development of an efficient, reliable, controllable, cross-species gene targeting 
method.  
 To this end, efforts have been made to prove the practicality of group II introns for 
eukaryotic gene targeting.  Initially, it had to be determined whether group II introns 
could recognize and target eukaryotic sequences (Guo et al. 2001).  Group II introns were 
designed to insert into sequences from the HIV-1 provirus and the human gene encoding 
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the HIV-1 co-receptor CCR5.  Using the E. coli system developed to test the 
retargetability of group II introns, it was proven that group II introns could efficiently 
integrate into both the HIV-1 provirus and CCR5 DNA target sites in E. coli plasmid 
assays (Guo et al. 2001).   
 Subsequently, the E. coli assay was also used to show that a mutant %-globin gene 
could be repaired by group II intron-based delivery of functional exons into a plasmid 
vector containing the sequence of the deactivated %-globin gene (Jones et al. 2005).  
Functional exons 2 and 3 of the %-globin gene were cloned into DIV of a group II intron 
that had been retargeted to insert into the first intron of the %-globin gene.  To ensure 
proper repair of the gene, a canonical 3’ splice acceptor site was cloned upstream of the 
exons and a polyA signal was cloned immediately downstream of exon 3 (Jones et al. 
2005).  Following successful intron integration into the %-globin sequence using the E. 
coli system, the plasmid DNA carrying the corrected version of the %-globin gene was 
transfected into mammalian cells.  The cells expressed the RNA and protein 
corresponding to wild-type %-globin. 
 Whereas the previously mentioned experiments were performed in E. coli, Guo et 
al. 2001 demonstrated for the first time that group II introns retained activity in human 
cells and could successfully integrate into plasmid-borne therapeutically relevant DNA 
target sites (Guo et al. 2001).  In these experiments, in vitro-prepared RNPs designed to 
target the HIV-1 co-receptor CCR5 were introduced separately from the plasmid DNA 
targets using liposome-mediated transfection (Guo et al. 2001).  The RNPs were able to 
locate and insert into the plasmids with limited efficiency, detectable only by nested 
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PCR.  Overcoming the low targeting efficiencies of those early experiments is essential 
for developing group II introns into a viable tool for eukaryotic gene targeting.  We felt 
that correctable technical issues, such as inefficient delivery or disruption of the RNP 
complex by the transfection agent, were the likely reasons for the low targeting 
efficiencies (Guo et al. 2000).  Regardless, the need to improve the targeting efficiencies 
was obvious, and the potential impact made the investment in developing the technology 
worthy of the time and effort.   
To address the issue of targeting efficiency, we began by considering the possible 
problem areas affecting group II intron activity in eukaryotic cells.  In addition to 
addressing the technical issues related to RNP delivery, it quickly became evident that the 
in vivo magnesium concentration was suboptimal (Romani & Maguire 2002).  Based on 
in vitro targeting experiments, the optimal magnesium concentration was determined to 
be approximately 10 mM (Saldanha et al. 1999).  The high level of targeting in 
prokaryotes even at suboptimal magnesium levels in bacteria suggests that host factors 
may play a role in the targeting pathway.  However, to date, few examples of helpful 
prokaryotic host factors have been confirmed to have a significant effect on gene 
targeting.  Accordingly, we set out to determine conditions under which plasmid targeting 
could be improved in eukaryotes.  We hypothesized that addition of magnesium to the 
cellular environment would increase targeting efficiencies.  We also considered the need 
for efficient localization of group II intron RNPs to the nucleus and improved penetration 
of the eukaryotic chromatin structure, which could limit access to genomic targets.  
Finally, we reflected on the possibility that the cellular environment could be hostile such 
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that introduction of RNPs into the nucleus or cytoplasm would elicit a response that 
would neutralize the RNP activity.  In order to address these issues, we designed 
experiments to directly manage many of these potential obstacles. 
 The first experiments that I performed included the injection of group II intron 
RNPs into live zebrafish embryos.  Injecting in vitro-prepared RNPs allowed us to 
circumvent obstacles to expression and assembly of the RNP complex in the cell.  By 
eliminating the need to express the intron in vivo, we could bypass transcriptional and 
translational regulatory pathways that might inhibit RNP formation.  Injections also 
allowed us to control the amounts of RNPs introduced into the cell and regulate the 
intracellular magnesium levels.  The latter allowed for systematic determination of the 
optimal in vivo magnesium concentrations for efficient gene targeting in zebrafish 
embryos.  Finally, injecting into actively dividing embryos exposed the RNP to a 
dynamic cellular environment that presented opportunities for access to the chromosomal 
DNA, such as nuclear envelope breakdown and periods of DNA replication .  
2.1 Reconstitution of Group II Intron RNPs for Microinjection and TPRT Assays 
 
In order to ascertain the targeting capabilities of group II introns in eukaryotic 
cells, it was necessary to make RNPs that were purified and concentrated enough for 
microinjections. The development of an efficient Eschericia coli expression system for 
the L. lactis group II intron Ll.LtrB allowed us to express and purify the components of 
the Ll.LtrB group II intron RNP (Matsuura et al. 1997; Saldanha et al. 1999).  Matsuura 
et al. (1997) demonstrated that both the intron and the IEP could be expressed in vivo at 
sufficient levels for purification of either the LtrA protein alone or the fully reconstituted 
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RNP.  Protein expressed in E. coli can also be purified and combined with in vitro 
transcribed intron RNA following the self-splicing reaction to form active RNP 
complexes.  Testing of purified RNPs, prepared in this manner, proved that LtrA has RT, 
maturase and site-specific endonuclease activity (Matsuura et al. 1997).  Saldanha et al. 
(1999) showed that in vitro-reconstituted RNPs, composed of purified LtrA and the 
excised lariat intron RNA, are able to carry out in vitro target-primed reverse 
transcription (TPRT) reactions, under defined reaction conditions.  The ability to perform 
in vitro TPRT demonstrated that purified reconstituted RNPs are capable of locating the 
target site, reverse splicing and carrying out reverse transcription with a high degree of 
specificity and efficiency.   
For the experiments described here, I applied methods similar to those established 
for purification of LtrA and in vitro reconstitution of the RNPs (Matsuura et al. 1997, 
Saldanha et al. 1999).  For expression of the LtrA protein, E. coli cells were transformed 
with the plasmid, pIMP-1P.  The plasmid contains the LtrA ORF cloned downstream of a 
tac promoter and &10 Shine Dalgarno sequence in the pCYB2 vector backbone (New 
England Biolabs).  LtrA was expressed as a fusion protein with a C-terminal tag 
containing an intein-linked chitin-binding domain, enabling LtrA purification via a 
chitin-affinity column, followed by intein-cleavage.  For the in vitro transcription of wild-
type Ll.LtrB-'ORF intron RNA, I used the pACD2 intron-donor plasmid, which contains 
the Ll.LtrB-'ORF intron with an additional T7 promoter in DIV.  The intron contained 
the wild-type (WT) EBS sequences so it would recognize the WT target site.  The 
plasmid was linearized with restriction enzyme, NheI, just downstream of the intron and 
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used as the transcription template.   The precursor RNA generated using Ambion’s 
Megascript T7 Kit contained the intron RNA and flanking exons.  I performed self-
splicing reactions using the precursor RNA and combined the splicing products with 
purified LtrA protein to reconstitute RNPs, according to established protocols (Matsuura 
et al. 1997, Saldanha et al. 1999). 
To verify that the in vitro-prepared RNPs were active, I performed in vitro TPRT 
reactions.  The TPRT assay is an indicator of the targeting activity for a given RNP 
preparation.  A schematic diagram of the TPRT method is shown in Figure 2.1a.  For the 
TPRT assay presented in Figure 2.1b, WT RNP particles were incubated with an 
unlabeled target plasmid, pBRR3-ltrB, which contained a 269-bp sequence corresponding 
to the Ll.LtrB insertion site from -178 - +91 from the site of intron insertion.  Following 
reverse splicing and endonucleolytic cleavage of the target plasmid, reverse transcription 
of the intron incorporated ["-32P]-dTTP and other dNTPs, which were present in the 
reaction mixture. 
The products were analyzed by separating them using agarose gel electrophoresis 
and autoradiography for detection of 32P-labeled plasmid bands that have incorporated 
nascent cDNAs.  Figure 2.1b shows a typical phosphorimage of an agarose gel containing 
the separated reaction products after incubating the WT RNPs with either the WT target 
plasmid pBRR3-ltrB (lane 2) or the negative control plasmid pBRR3-CCR5 (lane 1).  
The annotated autoradiograph shows that the reconstituted RNP particles are capable of 
carrying out the TPRT reaction and incorporating the radiolabeled-dTTP into high 
molecular weight plasmid-containing bands.  The negative control plasmid confirms that 
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intron integration occurs preferentially into the pBRR3-ltrB plasmid, presumably at the 
wild-type target site, while not recognizing an unrelated target site located in the pBRR3-
CCR5 plasmid.  Signal observed in the autoradiograph below the targeted plasmid 
corresponds to cDNAs synthesized from free RNAs that are present in the RNP 
preparation.  These RNAs are carried over from the transcription and splicing reactions 
and are able to act as templates for reverse transcription by LtrA under the TPRT 
conditions.  
2.2 Plasmid Targeting in Zebrafish Embryos 
The zebrafish plasmid-targeting assay is based on an assay developed in our lab to 
test group II intron mobility in E. coli (Guo et al. 2000, Karberg et al. 2001).  The E. coli 
assay is dependent on the Ll.LtrB intron, which is expressed in vivo from the donor 
plasmid, pACD2, integrating into a target site (the ligated E1-E2 sequence of the ltrB 
gene) cloned upstream of a promoterless tetR gene in an AmpR recipient plasmid, pBRR3-
ltrB.  The intron donor plasmid used for both the zebrafish and the E. coli assay contains 
a modified version of the Ll.LtrB intron in which a phage T7 promoter is inserted in 
domain IV near the 3’ end of the intron replacing the ORF sequence that would normally 
encode the IEP.  Previous work showed that these intron modifications resulted in higher 
integration efficiencies and increased nuclease-resistance when compared to the full-
length intron in the E. coli assay (Guo et al. 2001).  Insertion of the intron into the target 
site enables the T7 promoter in DIV to activate the tetR gene in the presence of T7 RNA 
polymerase.  Integration efficiencies are measured by determining the ratio of 
(TetR+AmpR)/AmpR colonies.  The E. coli plasmid-targeting assay requires delivery of 
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the donor and recipient plasmid by electroporation to the cells.  Expression of the intron 
and protein from a T7lac promoter in the donor plasmid allows for the formation of 
active RNPs, which target the recipient plasmid in vivo.  By contrast, for the zebrafish 
assay, the WT RNPs are prepared ahead of time and injected into fertilized embryos 
separately from the recipient plasmid, pBRR3-ltrB.   
To assay group II intron targeting reactions in zebrafish embryos, I used WT in 
vitro fertilized zebrafish (Danio rerio) embryos.   In vitro fertilization was performed 
according to protocols described in The Zebrafish Book (Westerfield 2000).  The reaction 
components were injected into the fertilized embryos 15 min after fertilization.  A 
schematic diagram of the protocol used for the plasmid-targeting assay in zebrafish is 
shown in Figure 2.2.  The target plasmid pBRR3-ltrB containing the WT ltrB target site 
was injected first, followed within 1 min by Ll.LtrB RNPs reconstituted, as described 
above.  In all the zebrafish experiments, the DNA target plasmid and RNPs were injected 
using different needles to avoid prior mixing, and 10 to 25 embryos were injected for 
each experimental condition.  When additional MgCl2 was included in the reaction, it was 
mixed with the recipient plasmid to reach the desired concentration.  After incubation at 
30°C for 1 h, the embryos were pooled.  Nucleic acids were extracted from the 10-25 
pooled embryos and electroporated into E. coli HMS174(DE3), which expresses phage 
T7 RNA polymerase.  The cells were then plated on LB medium containing ampicillin 
with or without tetracycline to determine the mobility efficiency, as described above.  
Colonies growing on plates containing both TetR and AmpR were picked and used to 
inoculate liquid LB medium containing ampicillin and tetracycline.  The cultures were 
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incubated overnight at 37ºC while shaking.  To verify proper integration of the intron, 
plasmids were isolated from the overnight cultures and sequenced using a primer, pBRR-
MCS, that binds upstream of the target site and generates the 5’ junction sequence 
(Figure 2.3a).  Sequence from the isolated plasmids confirmed the intron integration at 
the target site in the recipient plasmid (Figure 2.3b). 
Initial plasmid targeting experiments in zebrafish were performed by injecting 
Ll.LtrB RNPs at a concentration of 0.1 mg/mL in a solution containing 0.25% phenol red, 
10 mM KCl, 10 mM MgCl2 and 40 mM HEPES, pH 8, while the target plasmid was 
dissolved in 0.25% phenol red in water.   These experiments determined that basal 
targeting was detectable at low efficiency (0.004%), as determined by the colony 
numbers.  However, owing to the previously mentioned studies indicating that group II 
introns are particularly sensitive to low Mg2+ concentrations, we followed-up with 
experiments in which additional MgCl2 was added to the target plasmid solution at 
concentrations ranging from 0 to 500 mM.  High concentrations of MgCl2 could not be 
included with the RNP because MgCl2 causes the RNP to aggregate and clog the 
injection needles.  Under these conditions, we measured the group II intron-integration 
efficiency.  This procedure allowed us to determine the optimal injected Mg2+ necessary 
for group II intron integration.   
As shown in Figure 2.4a and b, for zebrafish embryos, the highest integration 
efficiencies were obtained when the injected Mg2+ concentration was approximately 150 
mM.  Given that the zebrafish embryo has a volume of ~200 nL and the injection volume 
of the DNA/MgCl2 solution was ~10 nL, the calculated increase in intracellular Mg
2+ 
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resulting from the injection was 7.5 mM or higher if one corrects for the 77% of the 
embryo made up of the less permeable yolk (Hagedorn et al. 1998).  Therefore, the 
optimal Mg2+ concentration for group II intron targeting in zebrafish embryos is in the 
range of the optimum Mg2+ concentration for the DNA integration reaction (10 mM), as 
determined by in vitro experiments (Saldanha et al. 1999). 
While the optimal injected Mg2+ concentration was determined to be ~150 mM, 
when I performed experiments at 125 mM MgCl2, I found that the integration efficiency 
varied with different batches of RNPs and different batches of embryos such that the 
maximal targeting efficiencies ranged from 0.11% to 0.89%.  Further, in parallel 
experiments performed in Xenopus laevis by others in our lab, it was determined that the 
addition of dNTPs to the plasmid DNA/MgCl2 solution improved the reproducibility and 
overall targeting efficiency (Mastroianni et al. 2008).  By adding 3.125 mM each of 
dATP, dCTP, dGTP and dTTP under the pre-determined optimal magnesium conditions 
and using the highest quality RNPs, I was able to improve the targeting efficiency over 
600-fold above the basal targeting efficiency from 0.004% to 2.5%. 
Of course, the physiological effects of adding these reaction components to early 
stage zebrafish embryos needed to be analyzed in order for this to be considered a viable 
gene targeting method.  Accordingly, I examined the impact of the injections on the 
survivability of the embryos.  I found that, for zebrafish embryos, hatch rates after the 
double injection of the highest concentration of MgCl2 (500 mM) in the DNA solution 
followed by injection of the RNPs were 26-52% compared to 35% for a single injection 
of distilled water (Table 2.1). Thus, zebrafish embryos appear reasonably tolerant of the 
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high intracellular Mg2+ concentrations required to support high efficiency group II intron 
integration. Together, these experiments show that under appropriate conditions, the site-
specific group II intron-integration reaction can occur efficiently in zebrafish embryos 
without significant impact on embryo viability. 
2.3 Plasmid Targeting in Drosophila Embryos 
 
After demonstrating the activity of group II introns in zebrafish embryos, we set 
out to determine whether similar results could be obtained in embryos of the fruit fly, 
Drosophila melanogaster.  I performed plasmid targeting in Drosophila embryos using 
the same reaction components from the zebrafish experiments.  The WT RNPs were 
prepared, as previously described, using the WT Ll.LtrB-'ORF intron donor plasmid as 
the template for generating the intron RNA.   Further, the target plasmid, pBRR3-ltrB, 
was also identical to that used for the zebrafish injections.   
The injection techniques differed somewhat from those for zebrafish.  Rather than 
performing in vitro fertilization as with zebrafish, Drosophila embryos were obtained by 
setting up mating cages of wild-type (Oregon-R) flies.  Shortly after the females laid the 
fertilized eggs, the embryos were transferred to a block of agar where they were aligned 
along the edge until they were transferred to a glass cover slip coated with a fine film of 
glue to hold the embryos.  The embryos were briefly desiccated and covered with oil to 
prevent further drying.  Once the embryos were covered with oil, the cover slip holding 
the embryos was placed on a support block for injection. 
For the Drosophila injections, the volumes of RNP-containing solution and 
plasmid DNA solution were based on methods previously established for fly injections in 
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the laboratory of Dr. David Stein.  In this pilot study, the injection volume was not 
calculated exactly, however it was in the range of 0.5 nL based on visual estimates.  A 
total of 70 embryos were injected with both the RNP and the recipient DNA solutions.  
Similar to the zebrafish experiments, the injection of RNP was done separately from the 
DNA injection to prevent mixing prior to entering the embryo.  After both injections 
were complete, embryos were incubated at 30ºC for 30 min.  The embryos were 
subsequently removed from the cover slip by pipetting the entire collection of embryos 
from the slide and transferring them to an Eppendorf tube containing 
phenol:chloroform:isoamyl alcohol (25:24:1 by volume; phenol-CIA) for DNA extraction 
and removal of the oil coating.  To increase the volume of the aqueous phase for the 
phenol-CIA extraction, 50 µL of distilled H20 was added to the mixture.  After the 
extraction, the aqueous phase, presumably containing the embryo DNA was further 
diluted by adding 500 µL of SNET buffer and 10 µL of 20 mg/mL proteinase K in water.  
The solution was incubated for 1 h at 55°C and again extracted with phenol-CIA to 
remove residual lipids and proteins.  The aqueous phase was subjected to ethanol 
precipitation to purify the nucleic acids.  The resulting pellet was resuspended in distilled 
water for transformation.  E. coli HMS174(DE3) were electroporated with the extracted 
nucleic acids and the cells were subsequently plated on LB medium containing ampicillin 
with or without tetracycline to determine the mobility efficiency, as previously described.  
Three separate transformations using the same extracted DNA sample showed that 
without any added MgCl2, the basal targeting efficiency in Drosophila embryos ranged 
from 0.003% to 0.008%.  Theoretically, additional MgCl2 in the reactions would have 
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increased the targeting efficiencies, as in the zebrafish experiments.  In fact, subsequent 
experiments performed by others in our lab verified that targeting efficiencies could be 
improved with the addition of MgCl2 and dNTPs, increasing targeting efficiencies to as 
high as 9.5% (Mastroianni et al. 2008). 
2.4 Genome Targeting in Zebrafish 
 
 Although plasmid targeting in zebrafish embryos was a significant 
accomplishment and offered the promise of using group II introns in eukaryotic cellular 
systems, genome targeting with group II introns is the ultimate goal.  To this end, we 
sought to site-specifically insert a group II intron into the zebrafish genome in vivo.  We 
chose to target the mitf  (microphthalmia-associated transcription factor) gene because of 
its role in the development of the pigmented melanophore cells that give zebrafish their 
characteristic stripes (Lister et al. 1999).  Mitf is a basic helix-loop-helix/leucine zipper 
transcription factor that when inactivated leads to the phenotype known as nacre (Lister 
et al. 1999).  Homozygotes for this mutation lack melanophores throughout embryonic 
and larval development (Figure 2.5a) (Lister et al. 1999).  The absence of melanophores 
provides a quick and easy method of screening embryos for the nacre mutation since they 
lack the distinctive striped skin pattern for which the zebrafish is named. 
In order to test the ability of a group II intron to disrupt the mitf gene, we had to 
obtain an intron that successfully targeted the gene sequence.  To do this, we used a 
selection-based method established in our lab for isolating introns that insert into specific 
sequences (Guo et al. 2000).  We cloned the mitf cDNA sequence into a recipient vector 
upstream of a promoterless tetR gene and selected an intron from a combinatorial library 
! $*!
of introns with randomized target site recognition sequences (EBS and !) (Guo et al. 
2000).  We isolated an intron that inserts into the mitf gene 235 nucleotides downstream 
of the start codon (Figure 2.6a).  The insertion site is located approximately 24 
nucleotides upstream of the activation domain coding sequence (Figure 2.6b).  We called 
this intron mitf235s because it inserted into the sense strand of the mitf coding sequence 
at nucleotide position 235.  We called the donor plasmid pACD-mitf235s.  In the E. coli 
plasmid-targeting assay, the mitf-targeted intron was shown to have a mobility frequency 
of approximately 52% compared to wild-type (data not shown).  When preparing RNPs, 
we used the linearized donor plasmid pACD-mitf235s as a transcription template to 
generate the intron RNA, as previously described.  In vitro targeting activity for the mitf-
targeted RNPs was confirmed by TPRT (not shown).   
To test the in vivo activity of the RNP, I performed plasmid-targeting assays in 
zebrafish embryos using the mitf-targeted RNP, as described for the WT RNPs.  These 
experiments were performed before I had determined the optimal plasmid targeting 
conditions.  Thusly, the amount of MgCl2 included in these reactions (20 mM) was 
significantly below the optimal.  Therefore, I was unable to detect plasmid targeting 
using the E. coli-based plasmid assay.  Despite suboptimal conditions, I was able to PCR 
amplify the 5’ integration junction from plasmids extracted from the injected embryos 
(Figure 2.3c and d).  Having determined that the mitf-targeted RNPs retained targeting 
activity in vivo, we proceeded with experiments designed to target mitf at the genomic 
level in zebrafish embryos.   
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 For in vitro fertilization, we mated wild-type zebrafish with fish homozygous for 
the nacre mutation.  This ensured that the F1 progeny were heterozygous at the nacre 
locus.  The rationale for using heterozygotes was to ensure that only a single targeting 
event would be necessary to produce zebrafish embryos with the nacre phenotype.  
Embryos were fertilized in vitro, as previously described, and RNPs were injected up to 
the eight-cell stage.  Prior to this developmental stage, the normal permeability barriers 
between embryonic cells had not yet formed (Kimmel & Law 1985) and persistent 
bridges between the yolk cell and temporary bridges connecting sibling blastomeres 
allow for exchange of cytoplasmic contents (Kimmel & Law 1985).  Injections following 
the fifth cell division would prevent uniform distribution of the RNP, due to the 
formation of the permeability barriers, and the likelihood of mosaic fish would increase.  
Therefore, I avoided injecting fish after the third cellular division.  After injection, 
embryos were incubated at 28.5°C for 72 h, a period well after the pigmented 
melanophores become observable (24-48 hours) (Lister et al. 1999, Kimmel & Law 
1995).  Each injection experiment resulted in numerous embryos, ranging from 50 to 400 
in a single injection session, to be screened for pigmentation mutants.   
Table 2.1 shows a sample of the targeting experiments and summarizes the results 
of the screens.  Despite testing several different conditions including various dilutions of 
the RNPs, none of the embryos injected with the mitf-targeted RNPs exhibited a 
phenotype consistent with the nacre mutation.  In several experiments, unusual 
phenotypes were observed, but we were unable to associate these deformities with the 
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group II intron (Figure 2.5b).  It is common for embryos to be deformed simply due to 
injection injury. 
 A number of limitations regarding the zebrafish injection experiments led us to 
move away from this line of experimentation.  The central reason for ending these 
experiments was that the number of embryos that could possibly be injected and screened 
was limited to such an extent that rare targeting events would be difficult to detect.  An 
expert in zebrafish injections might be able to inject as many as 500-1000 embryos in a 
single experiment.  With survivability ranging from 50 to 75%, in a successful injection 
session, this would require a genome targeting efficiency of at least 1-4 x 10-3 for 
detection of a single targeting event.  Although the zebrafish plasmid-targeting assay 
confirmed that the RNP was capable of inserting into plasmid-borne targets with 
efficiencies as high as 2.5%, these plasmids were co-injected with the RNPs into the 
cytoplasm and lacked some of the barriers associated with genome targets such as the 
nuclear envelope, histones and other chromatin-associated factors.  Therefore we had no 
way of effectively determining the likelihood of isolating a genome-targeting event in 
zebrafish.  I decided that an experimental approach that allowed for larger-scale screens 
would be more likely to yield the kinds of numbers necessary for isolating the rare events 
expected from genome targeting with group II intron RNPs in eukaryotes.   
2.5 Discussion 
 
 In this chapter, I have shown that group II introns retain gene-targeting activity 
even after injection into live zebrafish and Drosophila embryos.  This is the first time 
group II introns have been shown to possess targeting capabilities in these two organisms 
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and offers a great deal of promise for the application of group II introns as a novel 
eukaryotic gene targeting technology.  While initial plasmid-targeting results revealed 
limited targeting efficiency for both zebrafish (0.004%) and Drosophila (0.008%), these 
results were consistent with low-level targeting observed for similar experiments 
previously performed using mammalian cells in our lab (Guo et al. 2000).  However, not 
only was I able to confirm that group II introns are active in zebrafish embryos, I also 
improved the targeting efficiency as much as 600-fold by injecting MgCl2 along with the 
target plasmid.  Further, recent experiments performed by others in our lab showed that 
plasmid targeting in Drosophila can similarly be enhanced by the addition of MgCl2 from 
background targeting levels to greater than 9.5% (Mastroianni et al. 2008). 
The sensitivity of the group II intron to the concentration of Mg2+ in zebrafish 
embryos is consistent with previous results observed for group II intron splicing activity 
in yeast mitochondria (Gregan et al. 2001).  In yeast mitochondria, decreased Mg2+ 
concentrations strongly inhibit the splicing of four different group II introns belonging to 
two different subclasses while having little effect on the splicing of any of the group I 
introns.  The impact of Mg2+ concentrations on group II intron splicing seems to be due to 
an effect on the intron RNA since each of the introns affected uses a different protein co-
factor (Gregan et al. 2001).  While the inhibitory effect of decreased Mg2+ in the yeast 
mitochondria experiments was specific to forward splicing, it can be assumed that reverse 
splicing, which is necessary for the gene targeting reaction, would be similarly affected.  
In the event that decreased Mg2+ concentrations inhibit both forward and reverse splicing, 
overcoming this problem must be considered for both reactions when expressing the 
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group II intron in vivo for gene targeting.  However, for our experiments, the injection of 
in vitro-prepared RNPs eliminates the need to overcome any inhibitory effect of low 
magnesium concentration on the forward splicing reaction.  Thus, when injecting group II 
intron RNPs into zebrafish and Drosophila embryos, it is only necessary to include 
additional Mg2+ to stimulate the reverse splicing reaction.    
With this in mind, for zebrafish, I was able to determine the optimal concentration 
of Mg2+ necessary to enhance the plasmid targeting efficiency.  When injecting the RNP 
at concentrations between 100 and 1000 ng/µL, I determined that highest targeting 
efficiencies were observed when the plasmid DNA was injected with approximately 150 
mM MgCl2.  Because the target DNA and MgCl2 were injected in a total volume of 10 nL 
and the embryo has a volume of ~200 nL, the calculated increase in intracellular 
concentration of Mg2+ (7.5 mM) approached the optimal in vitro targeting concentration 
of 10 mM (Saldanha et al. 1999).  It was common to observe targeting efficiencies 
between 0.18% and 0.89% even when the optimal concentration of MgCl2 was included 
in the reaction.  However, using highest quality in vitro-prepared RNPs and the addition 
of 3.125 mM dNTPs to the target plasmid/MgCl2 mixture led to plasmid-targeting 
efficiencies up to 2.5% in zebrafish embryos.  Targeting efficiencies of this magnitude 
would be highly desirable for genome targeting so I sought to determine whether group II 
introns were similarly effective for genome targeting in zebrafish. 
Experiments designed to test the usefulness of group II introns for genome 
targeting in zebrafish relied on the methods developed for plasmid targeting.  An intron 
designed to insert into the zebrafish mitf gene was isolated from a combinatorial library 
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of introns with randomized target site recognition sequences.  For in vitro-prepared 
RNPs, the intron RNA was transcribed from the linearized mitf donor plasmid.  RNPs 
were reconstituted by combining the excised intron lariat from the self-splicing reaction 
of the intron RNA with purified LtrA protein.  A series of genome targeting experiments 
was performed, wherein the RNPs were injected into heterozygous nacre zebrafish 
embryos during the one-cell to eight-cell stages, using different concentrations of RNPs 
with and without a second injection of additional of MgCl2.  The expected phenotype 
consistent with disruption of the mitf gene was not observed for any of the targeting 
experiments.  While these results reflect a low gene targeting efficiency, they should in 
no way be construed to assume that genome targeting is unachievable in zebrafish.  Since 
the time of these experiments, we have significantly improved our ability to produce 
highly active group II intron RNPs.  Further, because these experiments were performed 
before determining the optimal conditions for plasmid targeting, it can be assumed that 
experiments performed today could potentially offer a higher likelihood of success.  
Finally, while supplemental Mg2+ is necessary for efficient targeting activity, the addition 
of Mg2+ by injection separate from the RNP is a viable approach for future gene targeting 
experiments based on survivability results of double injections.  
For the experiments described here, we set out to address factors in eukaryotic 
cells that might inhibit or reduce the gene targeting activity of group II introns.  I 
confirmed that the intracellular magnesium level in zebrafish embryos limits the in vivo 
activity of the RNP.  To overcome this impediment, I raised the intracellular magnesium 
concentration during the targeting reaction by injecting additional magnesium with the 
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plasmid target with the impressive effect, increasing the targeting efficiency more than 
600 fold (from 0.004% to 2.5%) in zebrafish embryos.  We also sought to determine 
whether the intracellular environment would be hostile to the RNP.  Our results suggest 
that any negative cellular response to the intron was not sufficient to abrogate the plasmid 
targeting activity of the RNP in zebrafish embryos.  Further, I also confirmed that 
plasmid-targeting activity was retained in Drosophila embryos.  These two metazoan 
species are sufficiently evolutionarily divergent to suggest group II introns may be active 
in a broad range of eukaryotes.   
Although we wanted to extend the plasmid targeting ability of the group II intron 
to target the genome, I did not observe any genome targeting events when injecting RNPs 
targeted to the zebrafish mitf gene.  This could be due to many complicating factors such 
as failure of the RNP to localize to the nucleus or inhibition of targeting by the chromatin 
structure.  Even though the genome targeting experiments were inconclusive, it should 
not be assumed that the obstacles for genome targeting are insurmountable.  Future 
experiments using improved RNP preparations and thoroughly applying some of the 
lessons learned from the plasmid targeting experiments here may prove that group II 













(a) The TPRT reaction is an assay designed to test the targeting activity of a group 
II intron RNP in vitro.  The RNP particle is incubated with an unlabeled target plasmid, 
which contains a sequence corresponding to the intron-insertion site in 20 µL of TPRT 
Buffer [10 mM KCl, 10 mM MgCl2, and 50 mM Tris-HCl (pH 7.5)] containing dATP, 
dGTP, and dCTP (0.2 mM each), and 20 µCi of ["-32P]dTTP (3000 Ci/mmol; New 
England Nuclear, Boston, MA).   Following reverse splicing and endonucleolytic 
cleavage of the target plasmid, reverse transcription of the intron incorporates the ["-32P]-
dTTP and other dNTPs.  The reactions are initiated by addition of the RNP particles, and 
the mixtures are incubated for 30 min at 37°C.  Products are analyzed in a 1% agarose 
gel, which is dried and subsequently autoradiographed with a Typhoon TRIO 
phosphorimager (Amersham Bioscience).!!INJ!A typical phosphorimage of the agarose-
separated TPRT products after incubating the WT RNPs with either pBRR3-ltrB (lane 2) 
or the negative control plasmid pBRR3-CCR5 (lane 1).  The autoradiograph confirms 
that the reconstituted RNP particles can carry out the TPRT reaction in vitro, 
incorporating the radiolabeled dTTP into high molecular weight plasmid-containing 
bands.  Lane 2 confirms that intron integration occurs preferentially into the pBRR3-ltrB 
plasmid while not recognizing an unrelated target site located in the pBRR3-CCR5 
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plasmid (lane 1).  Signal observed in both lanes of the autoradiograph below the targeted 
plasmid corresponds to cDNAs synthesized from free RNAs that are present in the RNP 
preparation.  These RNAs are carried over from the transcription and splicing reactions 

































Figure 2.2 Schematic Diagram of the Group II Intron Plasmid-Targeting Assay in 
Zebrafish Embryos. 
 
The in vivo plasmid-targeting assay involves separate injections of the WT group 
II intron RNP and the target plasmid with specified amounts of MgCl2 into early stage 
zebrafish embryos.  The Ll.LtrB-'ORF intron has a T7 promoter cloned into DIV.   
Integration of the intron into the target site cloned upstream of a promoterless tetR gene in 
an AmpR target plasmid (pBRR3-ltrB) activates the expression of the tetR gene.  After the 
embryos are injected and incubated for 30 min at 30°C, nucleic acids were isolated and 
electroporated into E. coli HMS174(DE3).  The integration efficiency is calculated as the 
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Figure 2.3 Sequencing and PCR to Detect Site-Specific Intron Integration for Plasmid-
Targeting Assays in Zebrafish Embryos. 
 
(a) Verification of intron integration into the WT target site was confirmed by 
sequencing the target site of the target plasmid following extraction of nucleic acids from 
injected zebrafish embryos.  The zebrafish embryos were injected with WT RNPs 
separately from the recipient plasmid, pBRR3-ltrB to avoid prior mixing.  10 to 25 
embryos were injected for each experimental condition and incubated at 30°C for 1 h.  
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After incubation, the embryos were pooled and nucleic acids were extracted and 
electroporated into E. coli HMS174(DE3).  The cells were then plated on LB medium 
containing ampicillin with or without tetracycline to determine the mobility efficiency 
based on the ratio of (TetR+AmpR)/AmpR colonies.  Colonies growing on plates 
containing both TetR and AmpR were picked and used to inoculate liquid LB medium 
containing ampicillin and tetracycline.  The cultures were incubated overnight at 37ºC 
while shaking.  To verify proper integration of the intron, plasmids were isolated from the 
overnight cultures and sequenced using a primer, pBRR-MCS (p1), which binds 
upstream of the target site and generates the 5’-junction sequence.  (b) Sequence from the 
isolated plasmids confirmed the intron integration at the target site in the recipient 
plasmid.   (c) Similar to the assay for WT plasmid targeting, mitf-targeted RNPs were 
injected into zebrafish embryos separately from the target plasmid, pBRR3-mitf.  
Following incubation, nucleic acids were extracted and used as a template for PCR to 
detect intron integration.  Primers used to detect intron integration were LtrB reverse 
bottom 1 and Upstream mitfa/b Top (1).  (d) The expected size of the PCR product 









































Figure 2.4. Determination of Optimal Magnesium Concentrations for Site-Specific 
Integration of Group II Intron RNPs into a Plasmid Target Site in Zebrafish Embryos. 
 
For group II intron plasmid targeting assays in zebrafish embryos, target plasmid 
(0.5 mg/ml in a solution containing 3.125 mM of each dNTP and specified amounts of 
MgCl2, with 0.25% phenol red) and Ll.LtrB-#ORF RNPs (0.1-1.0 mg/mL with 0.25% 
phenol red, 10 mM KCl, 10 mM MgCl2, and 40 mM HEPES, pH 8.0) were injected 
separately into 10 to 25 one-cell to eight-cell embryos. The injection volumes were ~5-10 
nL.  After injection, the embryos were washed with Steinberg's medium, pooled in a 
single 1.5-ml Eppendorf tube in 500 µl Steinberg's medium, and incubated for 30 min at 
30°C, prior to nucleic acid extraction and transformation of E. coli HMS174(DE3).  (a) 
Zebrafish embryos were injected with target plasmid DNA solution containing 0 to 150 
mM MgCl2 and (b) 0 to 500 mM MgCl2 followed by injection of WT Ll.LtrB RNPs.  
Integration efficiencies (%) for both experiments were determined based on the ratio of 
(TetR+AmpR)/AmpR colonies.  Optimal plasmid targeting was observed when the target 


























































Figure 2.5 The nacre Mutant and Deformed Embryos Observed During mitf Targeting 
Experiments 
 
(a) Lateral view of the wild-type (top) and nacre (bottom) larvae at 3-days post-
ferilization.  Embryos homozygous for nacre lack all neural crest-derived melanophores.  
Adapted from Lister et al., 1999.  (b) “Bent Tail” and “Anteriorized” mutants observed 
during injections targeting the mitf gene in zebrafish embryos.  Similar deformities were 
commonly observed in the genome targeting experiments, but could never be associated 




















Figure 2.6 Ll.LtrB Intron Target Site for the mitf Gene in the Zebrafish Genome and the 
Corresponding Location in the Mitf Protein 
 
(a) Alignment of the intron EBS1, EBS2 and ! sequences with the DNA target 
site sequences (IBS1, IBS2 and !’) in the zebrafish genomic sequence for the mitf gene.  
The mitf-targeted intron was selected from a combinatorial library of introns with 
randomized target site recognition sequences (EBS and !) (Guo, 2001).  The intron 
inserts into the mitf gene 235 nucleotides downstream of the start codon.  (b) The 
insertion site (red arrow) is located approximately 24 nucleotides upstream of the 






















Survival Percent nacre 
1-cell Sham injection 0.00 29/50 58% 0% 
1-cell DNA in water 0.00 40-60/400 10-15% 0% 
1-cell 1.0 0.00 8/100 8% 0% 
1-cell 1.0 0.00 8/150 5.30% 0% 
1-cell 0.1 0.00 23/200 11.50% 0% 
1-cell 0.1 0.00 0/50 0% 0% 
8-cell 0.1 0.00 9/50 18% 0% 
2-cell 0.1 0.00 20/150 13% 0% 
1-cell 0.05 0.00 6/40 15% 0% 
1-2 cell 0.15 0.00 14/88 16% 0% 
1-2 cell 0.15 0.50 31/60 52% 0% 
1-2 cell 0.15 0.50 18/68 26.50% 0% 
1-2 cell dH2O 0.00 54/156 34.60% 0% 
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The results of a series of genome targeting experiments are summarized in this table.  
Despite injections at various stages with different amounts of RNP and in some cases 
high concentrations (500 mM) of MgCl2, no embryos were observed with the nacre 
phenotype.  Importantly, the viability of embryos was not affected by injections with 500 
























CHAPTER 3: GROUP II INTRON-BASED GENE TARGETING IN 
MAMMALIAN CELL CULTURE 
 
 Because the original experiments in our lab demonstrated that group II introns 
retain retrohoming activity for plasmid targets in eukaryotic cells, a great deal of research 
has been carried out to direct them to target the chromosomes (Guo et al. 2000, 
Mastroianni et al. 2008).  Unpublished experiments performed in our lab by others have 
produced additional data to suggest that it is only a matter of time before group II introns 
will become a breakthrough technology for eukaryotic gene targeting.  For example, it 
has been verified by PCR that group II introns can locate and insert into specific target 
sites even within the highly complex environment of purified chromosomal DNA via in 
vitro TPRT reactions (Cui 2005).  Group II introns have also targeted chromosomal DNA 
in mammalian cell nuclear lysate without additional Mg2+ suggesting that intracellular 
Mg2+ levels are sufficient for gene targeting (Cui 2005).  In addition, Ll.LtrB group II 
intron RNPs have been delivered to mammalian cells by electroporation and 
immunofluorescence using an anti-LtrA antibody showed that at the protein component 
of the RNP localized to the nucleus of HEK 293 cells.  Nuclear localization of the protein 
does not guarantee that active RNPs also did so.  However, it was confirmed by PCR that 
electroporated group II intron RNPs designed to insert into multicopy rDNA targets site-
specifically integrated into the chromosome (Cui 2005).  This suggests that some active 
RNPs had properly localized to the nucleus.  Despite successful PCR amplification of 
these targeting events, isolating a viable mammalian cell with a group II intron-based 
targeting event has yet to be accomplished.  In addition, insertion events to date have 
! &'!
only been detected when targeting multicopy target sites or a single copy reporter 
construct.  Targeting of a single-copy endogenous gene has not yet been shown. 
Developing the best method for using group II introns in mammalian cells is 
critical for this technology to become useful for gene therapy-related purposes.  In pursuit 
of this method, we have tested group II introns for eukaryotic gene targeting in a variety 
of experiments.  Some of the drawbacks of previous experiments performed in our lab 
include: 1) the lack of a positive control for experimental comparisons; 2) the 
inefficiencies associated with the group II intron targeting activity in eukaryotic cells, 
especially regarding single target sites; and 3) the inability to enrich for and isolate living 
cells containing group II intron-based targeting events.  Developing an assay that 
addresses these problems was a goal that I chose to pursue.  Meeting this goal would 
improve the overall experimental approach for understanding the targeting behaviors of 
and the conditions necessary for group II introns in eukaryotic cells.   
By combining the unpublished data from our lab with existing gene targeting 
methods, I developed the experimental approaches described in this chapter.  I will 
discuss experiments in which I use group II intron RNPs to create a double-strand break 
at a single target site in the genome that facilitates, via intermolecular recombination, the 
site-specific incorporation of an exogenous donor DNA molecule.  While the first 
demonstration of RNP-stimulated integration used a linearized double-stranded donor 
DNA, use of the single-stranded genome of recombinant adeno-associated virus (rAAV) 
improved our method of donor DNA delivery.  The rAAV experiments generated 
promising data to suggest that group II introns can stimulate integration of the donor 
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DNA at the target site and act as a eukaryotic gene targeting technology.  These 
experiments offer at least two improvements upon the experimental design of previous 
gene targeting experiments in our lab.  First, we can isolate cells containing site-specific 
targeting events that have presumably been stimulated by group II intron induced double-
strand breaks.  Second, by using rAAV to deliver the donor DNA, we have a reliable 
method for determining a positive control level of targeting that serves as the baseline for 
comparisons with group II intron experiments.  Through these improved experimental 
approaches, I have obtained data to suggest that group II intron RNPs can stimulate the 
site-specific integration of exogenous DNAs. 
3.1 Preparation of CCR5-Targeted Group II Intron RNPs and In Vitro Targeting 
Experiments 
 In 2001, Guo et al. designed group II introns to insert into therapeutically relevant 
targets.  The %-chemokine receptor gene, CCR5, was chosen as a potential target because 
of its well-understood role in facilitating HIV infection of T lymphocytes (Deng et al. 
1996).  CCR5 is commonly used for novel gene targeting technologies as a proof-of-
principle target gene.  Several introns were designed to target the CCR5 gene with 
varying degrees of targeting efficiency (Figure 3.1b).  Of the five group II introns 
designed to target CCR5, one had a particularly high targeting efficiency of 53% +/- 8% 
compared to the WT Ll.LtrB intron in the E. coli mobility assay (Figure 3.1b) (Guo et al. 
2000).  The insertion site for this intron was located at nucleotide 332s of the major 
product of the CCR5 cDNA, which at the genomic level corresponds to exon 4 (Figure 
3.1a and c) (Mummidi et al. 1997).  Guo et al. prepared purified RNPs using the CCR5-
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targeted intron.  HEK 293 cells were transfected with the RNPs and a plasmid DNA 
containing the CCR5 target site using a liposomal formulation (DMREI-C) designed for 
efficient nucleic acid transfection of mammalian cells (Guo et al. 2000).  Nested PCR 
confirmed that the RNPs located and inserted into their target sites in the plasmid DNA.  
These experiments are the basis upon which I designed new experiments for targeting the 
CCR5 gene in human cells using the CCR5-targeted RNP. 
 In order to utilize CCR5-targeted RNPs for genome targeting, it was necessary to 
produce high quality in vitro-prepared RNPs.  Following RNP preparation procedures 
similar to those described in Saldanha et al. (1999) and previously described for the 
zebrafish RNP injection experiments, I prepared CCR5-targeted RNPs for mammalian 
genome targeting experiments.  The RNP particles were reconstituted by combining 
purified LtrA protein and excised lariat intron RNA obtained by in vitro self-splicing of 
the CCR5-targeted Ll.LtrB RNA (pACD2-CCR5(332s)/NheI in vitro transcript).  As 
previously mentioned, the RNA included in the RNP reconstitution contains 
heterogeneous RNAs 60-70% of which is intron lariat while the remainder consists of 
precursor RNA and splicing products including ligated exons and linear intron RNA.  
Therefore, when determining the RNA concentration by O.D.260, it is difficult to specify 
the exact amount of protein to include in the RNP reconstitution.  In order to determine 
the optimal amount of protein to include in the reconstitution reaction, I reconstituted 
RNPs with different amounts of protein and tested each of the resulting RNPs for TPRT 
activity (Figure 3.2).  The most active RNP, as determined by this method, is used in 
targeting experiments.  The CCR5-targeted RNPs were regularly more active in the 
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TPRT reactions than WT RNPs prepared in parallel using similar reagents, as can be seen 
in Figure 3.2.   
In addition to the standard plasmid-based TPRT reactions, I performed “cold” 
TPRT reactions using genomic DNA as the target.  Cold TPRT reactions consist of 
similar reactants to the standard TPRT reaction, but no radiolabeled nucleotides are 
included in the reaction and purified human genomic DNA replaces the plasmid DNA as 
the target.  In order to detect targeting, I performed PCR to amplify the 3’-integration 
junction.  Successful amplification across the 3’ junction suggests that the intron has 
correctly inserted at its target site and reverse transcription of the intron is complete, up to 
the annealing point for the PCR primer (Figure 3.3a).  The 586-bp PCR product 
corresponding to the 3’ junction was readily amplified from a plasmid targeting 
experiment that was performed parallel to the genome targeting experiment (Figure 3.3b).  
Targeting products were less efficiently amplified from the genomic DNA targeting 
experiment.  However, the 492-bp amplicon corresponding to the 3’ junction was 
detectable, verifying that the CCR5 RNP could find its target site even within a more 
complex genetic environment.  Dilution of the genomic DNA in the reactions determined 
the minimum level of detection under these conditions (Figure 3.3b).  Based on the 
amounts of genomic DNA used in the cold TPRT reactions (50 ng, 5.0 ng and 0.5 ng), I 
determined that in vitro targeting of the CCR5 gene could be visibly detected on an 
agarose gel in as few as 1,510 genomes (Figure 3.3b), using 3.3 pg as the approximate 
mass of one human genome.   PCR confirmation of in vitro targeting suggested that 
genome integrations would be detectable even among more complex DNA mixtures. 
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3.2 Delivery of RNPs by Electroporation and In Vivo Targeting of CCR5 by Direct 
Integration 
Electroporation uses a high voltage pulse to increase the permeability of the cell 
membrane in order to increase the transmembrane transport of molecules that otherwise 
cannot enter the cell.  Electroporation is commonly used to deliver DNA and naked RNA 
to mammalian cells.  A less common application of electroporation is for the transfection 
of cells with ribonucleoprotein complexes.  Li et al. developed one of the first RNP 
electroporation methods using influenza virus RNPs (Li et al. 1995).  Subsequently, our 
lab established appropriate conditions for delivering group II intron RNPs to HEK 293 
cells (230 V, 250 µF) (Cui 2005).  By fusing GFP to the protein component of the RNP, 
the protein was shown to localize to the nucleus of the cells (Cui 2005).  In follow-up 
experiments using the established electroporation methods, rDNA-targeted RNPs were 
delivered to HEK 293 cells.  PCR amplified the intron inserted at the appropriate rDNA 
target site.   
For the experiments described in this chapter, I used a similar approach to deliver 
CCR5-targeted RNPs to two different mammalian cell lines: K562 (human hematopoietic 
cell line) and HCT116 (human colorectal cancer cell line).  The electroporation 
conditions for these experiments are described in Table 3.1.  The electroporation 
conditions for K562 cells were based on conditions previously shown to deliver DNA 
using the Gene Pulser II electroporation system (Bio-Rad Laboratories, Electroprotocols 
Bulletin #D035551).  Based on these conditions, the voltage and capacitance were set to 
320 V and 800 µF, respectively.  Because there was no established protocol for 
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delivering RNPs to HCT116 cells, I tested both the previously described sets of 
electroporation conditions from the HEK 293 cell and K562 cell experiments.    
To test the conditions for delivering RNPs to K562 cells, I sought to disrupt the 
CCR5 gene by direct intron integration.  Direct integration of a group II intron at the 
target site is one of the most straightforward ways to disrupt a gene at the genomic level.  
Although Cui was able to detect targeting events for rDNA after electroporating RNPs 
into HEK 293 cells, rDNA is a multicopy target.  Multicopy targets offer more 
opportunity for targeting; and their distribution along the chromosome very likely 
corresponds to varying degrees of chromatin condensation.  rDNA genes have a copy 
number of 400 per human cell and are actively transcribed in dividing cells (Yoon et al. 
1995, Gencheva et al. 1996).  A group II intron has also targeted a single copy marker 
gene integrated into the genome, however it is possible that the target integrated at a 
recombination “hot spot” so this group II intron integration event is not typical of an 
endogenous gene.  Targets like the actively transcribed rDNAs and the integrated 
selection marker will likely be more targetable due to sufficient chromatin “openness” 
than more obstructed target sites such as non-transcribed genes.  The single copy CCR5 
gene is likely to be a more difficult target to disrupt depending on the chromatin 
condensation around the target site.  In order to increase our chances of targeting CCR5, 
we chose the K562 cell line that is known to express the CCR5 gene (Mummidi et al. 
1997, Mondal et al. 2005).  Transcription would likely provide a more open chromatin 
structure.  This we hypothesized would improve the accessibility of the target site to the 
group II intron RNP. 
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To test our hypothesis, I delivered in vitro-prepared CCR5-targeted RNPs by 
electroporation to mammalian cells in order to disrupt the CCR5 gene by direct 
integration.  Experiments in zebrafish, Drosophila and Xenopus laevis that demonstrated 
the enhancing effects of MgCl2 on group II intron targeting activity led me to include 
MgCl2 in some reactions (Mastroianni et al. 2008).  Figure 3.4 shows the results of nested 
PCR to detect the 3’ junction of the intron at the target site following electroporation of 
the RNP into K562 cells.  The same primers used for the cold TPRT experiments 
performed with purified genomic DNA were used for the primary PCR.  The primers 
used for nested PCR were the intron-specific primer, ltrB 890s, and the CCR5-specific 
primer, CCR5 +156-+135.  In this experiment, while most samples received a total of 10 
µg of the CCR5-targeted RNP, only the sample that received 20 µg of RNP had a distinct 
PCR product of the appropriate size (211 bp) (lane 6, Figure 3.4).  The PCR product was 
not detected in cells receiving no electroporation pulse and/or no RNP.  The addition of 
MgCl2 with 10 µg of RNP did not seem to have any effect on the reaction nor did 
decreasing the number of cells in the reaction from 5 ( 106 to 5 ( 105. While these results 
were promising, I was unable sequence the PCR product to confirm that it reflected a true 
integration event.  Further, there was no way to enrich for cells with the CCR5 gene 
disruption.  This limitation led us to pursue experiments to achieve this important 




3.3 Targeting the CCR5 Gene In Vivo by Group II Intron RNP-Stimulated 
Homologous Recombination  
Based on the promising results for the in vivo targeting of the CCR5 gene in K562 
cells, we felt that the group II intron RNP could potentially be used in at least 3 different 
ways for gene targeting; 1) to disrupt genes by direct integration, 2) to generate a double-
strand break that leads to mutagenic repair by NHEJ, and 3) to generate a double-strand 
break that stimulates the incorporation of donor DNAs by homologous recombination.  In 
most cases, disrupting genes by direct integration does not allow for enrichment of 
successfully targeted cells because there is often no selectable phenotype for the 
disrupted target gene, as is true for the CCR5 gene.  Although a selectable marker can be 
incorporated into the intron, its presence is expected to decrease the efficiency of the 
group II intron integration reaction (Frazier et al. 2003, Plante & Cousineau 2006).  
Therefore, use of the group II intron to create a double-strand break that stimulates the 
integration of an exogenous DNA fragment carrying a selectable marker is an attractive 
method for targeting and isolating live cells containing gene disruptions. 
3.3.1 Designing the Plasmid Donor DNA for Targeting the CCR5 Gene  
Our lab has previously demonstrated that lariat-containing group II intron RNPs 
can create double-strand breaks that stimulate homologous recombination in E. coli and 
in Xenopus laevis oocytes (Mastroianni et al. 2008, Karberg et al. 2001).  The early steps 
of the retrohoming process cleave the DNA.  First, the 3’ end of the intron RNA reverse 
splices into the top strand of the DNA target site.  Next, the IEP cleaves the bottom strand 
approximately 10 nucleotides downstream of the RNA insertion site.  The double-strand 
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break persists until the 5’ end of the intron RNA forms a covalent bond with the 3’ end of 
the 5’ exon.  As previously depicted in Figure 2.1b, partial reverse splicing, in which the 
5’ end of the intron fails to bond with the 5’ exon, represents a significant percentage of 
the targeting events in the in vitro TPRT reaction and varies with RNP batches (Zhuang 
et al. 2009, Saldanha et al. 1999).  The mechanism by which group II introns stimulate 
HR-based incorporation of exogenous DNAs is assumed to be similar to that described 
for other site-specific endonucleases.  While both linear and lariat-containing group II 
intron RNPs can stimulate HR, Mastroianni et al. (2008) showed that group II intron 
RNPs containing lariat intron RNA have a somewhat higher stimulatory effect than group 
II introns containing linear intron RNA.  Using group II introns as a site-specific 
endonuclease to facilitate successful integration of the donor DNA will result in 
disruption of the target gene and will allow for enrichment using the selectable marker 
present in the donor DNA. 
 To test whether group II introns can create double-strand breaks that stimulate 
integration of a donor DNA molecule at the target site in cultured mammalian cells, we 
designed a pick-up fragment (PUF) donor DNA, pCCR5-PUF2, that would incorporate at 
the CCR5 gene by homologous recombination (HR) (Figure 3.6a).  The design of the 
PUF construct is based on standard HR DNA constructs used in classical gene targeting 
experiments in which regions of sequence homology flanking the desired insertion site 
are located on either side of a selection marker (Doetschman et al. 1988, Bronson & 
Smithies 1994).  Two regions of homology were amplified by PCR from the CCR5 gene; 
the first beginning 25 bp 5’ of the target site and extending 2.2 kb upstream, including a 
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portion of intron 2 and exon 4, and a second fragment beginning 15 bp 3’ of the target 
site and extending 4.1 kb downstream, consisting of a portion of exon 4 and intron 3 
(Figure 3.6a).   The 40 base pairs directly flanking the target site were omitted from the 
construct in order to prevent the RNP from recognizing and targeting the donor DNA 
molecule prior to or following insertion.   
Sedivy and Dutriaux (1999) demonstrated that configuring a targeting construct as 
a promoter trap such that marker gene expression is dependent on the endogenous gene 
promoter results in significant enrichment for homologous recombinants within the pool 
of transgenic clones.  Thus, an ATG (-) blasticidin resistance gene ORF was cloned in 
frame with the homology arm containing the upstream coding sequence of exon 4 from 
the CCR5 gene.  By fusing the blasticidin gene to the CCR5 ORF, expression would 
necessarily be driven by endogenous transcription from the CCR5 promoter upon 
integration and successful targeting events could be selected based on blasticidin 
resistance.   
The donor DNA was constructed in a pUC19 plasmid backbone in such a way 
that linearization (MluI digestion) of the vector was necessary to free the ends thereby 
allowing the targeting vector to take on an “ends-out” arrangement when aligned along 
the targeted chromosome (Figure 3.6a).  The “ends-out” design of the targeting vector is 
commonly considered a “replacement vector” and is often used in yeast and mouse for 
gene targeting (Figure 3.5) (Müller 1999, Gong & Golic 2003).  Essentially, the 
replacement vector is designed such that homologous sequences within the PUF are 
colinear with the target sequences.  A double crossover event replaces chromosomal 
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sequences with the vector sequences (Müller 1999).   In this case, the blasticidin selection 
cassette and the pUC19 vector backbone would replace the 40-bp sequence 
corresponding to the group II intron recognition site (Figure 3.6a).  Because the construct 
was designed to encode a CCR5 truncated fusion protein, cells exhibiting blasticidin 
resistance due to non-specific integration events would be reduced to only those 
insertions that resulted in fusions with upstream exons of other genes.  We felt this would 
give us high confidence in any blasticidin resistant colonies that arose during the 
selection process.  By introducing the PUF donor DNA into K562 cells along with the 
CCR5-targeted RNP, we expected an increased efficiency of PUF integrations at the 
target site following cleavage of the target DNA as has been observed with other double-
strand break-stimulated gene targeting experiments.   
3.3.2 Electroporation of K562 Cells with RNP and Donor DNA, Selection Methods 
and Panning for PUF Insertions 
Using similar conditions to those described above for the direct integration 
experiments, I delivered RNPs along with the linearized pCCR5-PUF2 donor DNA to 
K562 cells.  For this experiments, I referred to electroprotocols established for the Bio-
Rad Gene Pulser for the delivery of DNA to K562 cells (Bio-Rad Laboratories, 
Electroprotocols Bulletin #D035551).  Both the donor DNA and the RNP were 
resuspended in HKM buffer [10 mM KCl, 10 mM MgCl2, and 40 mM HEPES, pH 8.0], 
which was developed in our lab for optimal resuspension of group II intron RNPs.  
During the electroporation, cells were suspended at 5 x 106 cells/mL in 800 mL of IMDM 
medium (Invitrogen).   This experiment included a constant concentration of donor DNA 
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(approximately 10 µg) combined with varying concentrations of CCR5-targeted RNP 
(12.5 µg, 25 µg and 50 µg).  The RNP and DNA were added separately to the cell 
suspension immediately prior to electroporation.  Following electroporation (Voltage: 
320 V, Capacitance: 800 µF), the cells were transferred to a T-75 culture flask containing 
50 mL of growth medium without FBS and incubated at 37ºC for 1 h.  After 1 h, the 
medium was exchanged, and the cells were incubated overnight in complete medium 
without selection.  Although the cell viability was significantly reduced for each of the 
samples that received the RNP along with the DNA, after 48 hours of recovery, the 
selection process for gene targeting events was initiated by adding blasticidin (5 µg/mL) 
to the medium.   
Cells resistant to blasticidin were tracked by counting live cells in each of the 
samples (Figure 3.8).  Five days post-electroporation, the concentration of blasticidin was 
increased to 10 µg/mL.  Despite the addition of 10 µg/mL of blasticidin to the medium, 
the cells maintained a steady increase until day 8, when it appeared that the blasticidin 
inhibition began to take effect by significantly decreasing the number of live cells.  Either 
by error or technical failure, most samples appear to have been released from selective 
pressure from day 8 until day 9.  However, by day 11, after refreshing the selection 
medium, the cells again underwent significant cell death.  From day 13 until day 21 post-
electroporation, the number of live cells in all samples except the positive control (sample 
7) was greatly reduced.  The positive control sample had been transfected with a plasmid 
expressing the blasticidin resistance gene from a constitutive promoter and therefore was 
expected to contain cells resistant to the antibiotic.  Beginning on day 14, the positive 
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control (Sample 7) had nearly 10 times more live cells than each of the other samples.  
However, by day 26, samples that received both the RNP and the donor DNA (Samples 
4-6) began to approach the number of live cells observed in the positive control.  By day 
29, cells in the sample that received neither the donor DNA nor the RNP (Sample 1) and 
cells that received either the donor DNA alone (Sample 2) or the RNP alone (Sample 3) 
were entirely eliminated by blasticidin selection (Figure 3.8).  At the same time, each of 
the samples that received both the RNP and the donor DNA (Sample 4-6) reached 
comparable cell survival numbers to those of the positive control (Sample 7) (Figure 3.8).  
At this point, the cell numbers were sufficient to begin DNA analysis to determine 
whether samples 4-6 contained PUF insertions at the CCR5 target site.  DNA was 
extracted from samples 4-7 to check for integration of the PUF at the target site (Figure 
3.8), however the cells at this stage consist of a heterogeneous pool of all the possible 
integration events.  Isolating individual blasticidin resistant cells from this pool will allow 
for the cell-specific characterization of the integration events, whereas analysis of the 
genomic DNA extracted at this stage will give an indication of whether site-specific 
integration has occurred in the heterogeneous pool of cells. 
Because the K562 cell line is a suspension cell line, isolating single drug-resistant 
cells is more difficult than when using an adherent cell line.  However, Anderson et al. 
developed a simple and efficient panning method for separating live cells growing in 
suspension from dead ones (Anderson & Junker 1994).  The method takes advantage of 
the nearly universal presence of "-glucosyl and "-mannosyl residues on the outer surface 
of mammalian cell membranes.  The method relies on the fact that live mammalian cells 
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will adhere to plastic or glass surfaces coated with the plant lectin concanavalin A (con 
A) while dead cells will not.  A schematic diagram of the targeting and selection methods 
is included in Figure 3.7.  Each of the samples containing live cells (samples 4-7) was 
screened using the methods described in Anderson & Junker 1994.  Individual cells were 
picked from the plates where live cells had attached to the conA-treated surface.  The 
cells were transferred to 96-well plates for population expansion in order to generate 
enough cells for large-scale DNA extractions.  DNA extractions were performed on the 
isolated colonies and PCR was performed to screen for PUF integrations, but none of the 
selected colonies were conclusively shown to contain a site-specific integration of the 
PUF.     
3.3.3 PCR Analysis of the CCR5 Gene in Cells Targeted by RNP-Stimulated 
Homologous Recombination Using pCCR5-PUF2  
In order to characterize the blasticidin resistant cell populations from the CCR5 
targeting experiments, I analyzed the CCR5 gene region using a series of PCR strategies 
(Figure 3.9a).  Initially, the most direct way to detect an insertion at the target site was to 
amplify the blasticidin ORF at the CCR5 locus.  Because the homology arm upstream of 
the target site was approximately 2.2 kilobases, I designed two primers that annealed 5’ 
of this homology region so as to avoid amplification of the homology region from the 
donor DNA, p1 (CCR5 exon 1) and p2 (CCR5 exon 1b) (Figure 3.9).  Similarly, I 
designed two primers within the blasticidin resistance gene directed anti-parallel to the 
coding sequence, p9 (Blasticidin 2 anti) and p10 (Blasticidin 1 anti) (Figure 3.9).  The 
two sets of primers allowed for nested PCR reactions.  Using the outermost set of primers 
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(p1 and p10) including the 5’-most CCR5 primer and one inside the blasticidin ORF for 
the primary PCR resulted in an inconclusive gel with no specific amplification in any of 
the lanes corresponding to samples 4-7 or in an additional lane containing PCR products 
from genomic DNA of untreated K562 cells (sample 8) (Figure 3.9b).  Use of the primary 
PCR products as the template for nested PCR using primers that anneal just inside those 
of the primary PCR reaction resulted in amplification of a non-specific band in samples 
4, 5, 6 and 8 with a streak of non-specific amplification in the lane containing the sample 
6 PCR products (lane 3, Nested PCR gel, Figure 3.9b).  Upon closer inspection, it 
appeared that a faint band corresponding to a 2.6-kb PCR product was present in the lane 
for sample 6 (lane 3, Nested PCR gel, Figure 3.9).  Since this was the expected size for 
the desired amplification product in the event of PUF integration, I analyzed sample 6 
genomic DNA with much greater scrutiny.   
I designed primers positioned within the CCR5 gene at successively increasing 
distances upstream of the integration site for the blasticidin ORF (Figures 3.9a).  When 
combined with an anti-parallel blasticidin resistance gene primer (p10, Blasticidin 1 anti), 
the new CCR5 primers were designed to amplify PCR products ranging from 503 bp to 
2,601 bp (Figure 3.9a and c).  While each of the smaller PCR products could be amplified 
from randomly integrated donor DNA, the 2.6-kb fragment could only be amplified if the 
donor DNA had integrated at the target site (lane 2, Figure 3.9c).  The results of this PCR 
characterization of sample 6 genomic DNA increased our confidence that we had 
successfully inserted the donor DNA into the CCR5 gene.  Surprisingly, the amplification 
of the PUF insertion always required nested PCR, suggesting that the targeted DNA was 
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present in very low amounts.  Perhaps this is due to the fact that sample 6 was not a 
homogenous suspension of cells, but rather was a collection of cells many of which did 
not contain the site-specific PUF insertion.  In order to generate enough PCR products for 
sequencing, it was necessary to perform nested PCR using the 2.6-kb fragment as the 
template.  The nested PCR product as shown in Figure 3.9d was 2,479 bp and was 
successfully sequenced to confirm the amplification of the donor DNA at the CCR5 
target site.  
Additional PCR were performed to rule out the possibility that sample 6 was 
simply contaminated with the positive control plasmid expressing the blasticidin gene 
(Figure 3.10).  Each sample containing blasticidin-resistant cells was screened by 
amplifying sequences from inside the blasticidin-resistance coding sequence.  The 
blasticidin resistance gene was successfully amplified from samples 4-7 but not sample 8 
(Lanes 1-4, Figure 3.10a).  In order to rule out the possibility of contamination in these 
samples by the positive control plasmid these same samples were screened by PCR using 
primers in the CMV promoter and the blasticidin resistance gene that would only amplify 
a product if the positive control plasmid were present.  A product was only amplified 
from sample 7, which confirmed that the positive control plasmid is only present in this 
sample (Lane 4, Figure 3.10).  RT-PCR confirmed that blasticidin was expressed in 
sample 6 and sample 7 cells (Figure 3.10c).  Attempts to screen isolated colonies from 
the panning experiments for gene disruptions failed to yield any high-confidence colonies 




3.3.4 Southern Blot Analysis of RNP-Stimulated Homologous Recombination in 
Targeted K562 Cells 
 
 To further characterize sample 6, which was shown to have a detectable 
integration event by PCR, I designed a Southern blot strategy to confirm the integration 
at the CCR5 target site (Figure 3.11a).  This strategy involved the use of a DNA probe 
designed to anneal to the CCR5 genomic sequence just upstream of the 5’ end of the 5’ 
homology arm (probe 1, Figure 3.11a).  Genomic DNA extracted from cells of sample 6 
was digested with AflII.  The genomic DNA from non-targeted cells would result in a 
5.5-kb DNA fragment, while successful integration would yield a DNA fragment 8.7 kb 
in length (Figure 3.11a).  The results of the Southern blot were complicated by the fact 
that the genomic DNA of sample 6 was extracted from a heterogeneous pool of cells 
collected prior to panning for isolated antibiotic resistant cells.  Therefore, when blotting 
with the probe designed to anneal to the CCR5 gene just upstream of the targeting event, 
a band corresponding to the expected size of the integrated targeting vector was not 
detectable (Figure 3.11b).  In other words, the proportion of targeted genomic DNA was 
insufficient for detection among the heterogeneous WT (non-targeted) DNA. 
Subsequently, I designed a second probe to anneal to the blasticidin resistance 
gene (probe 2, Figure 3.11a).  This probe would verify the presence of the blasticidin 
ORF in the genomic DNA.  The Southern blot yielded a single band in each lane 
containing genomic DNA from blasticidin resistant cells (Figure 3.11c).  However, I was 
unable to distinguish the band corresponding to the genomic integration (8.7 kb) from the 
expected sized band for the linearized vector alone, which, albeit unlikely, may be 
present to some degree as extrachromosomal DNA (9.6 kb) (Figure 3.11c).  A number of 
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experiments were performed to isolate a single CCR5-targeted cell colony from sample 6 
to confirm that individual cells were positive for the gene disruption, but no conclusive 
evidence was found (data not shown).  Because the targeting efficiency using dsDNA as 
the donor DNA is so inefficient and site-specific double strand cleavage by the group II 
intron is also thought to be inefficient, we sought other methods of gene targeting that 
would improve our likelihood of detecting gene targeting events.  We found the rAAV-
based gene targeting method to be appropriate for these experiments.  
3.4 Targeting the CCR5 Gene In Vivo by Group II Intron RNP-Stimulated 
Integration of Recombinant Adeno-Associated Virus 
 
While introducing exogenous plasmid DNA as described above for site-specific 
homologous recombination has been a historically effective technique for gene targeting, 
the most innovative method for contemporary gene disruption is the use of recombinant 
adeno-associated viruses.  It has been shown that rAAV-based vectors integrate into 
homologous chromosomal loci 25-fold more efficiently than comparable plasmid vectors 
(Yanez & Porter 1998, Topaloglu et al. 2005, Russell & Hirata 1998).  With gene 
targeting efficiencies approaching 70% in some cases of rAAV targeting, we felt that 
utilizing rAAV would provide a reliable positive control level of baseline targeting upon 
which we could demonstrate a stimulatory effect attributable to double-strand breaks 
created by group II intron RNPs at the target site (Hirata et al. 2002, Kohli et al. 2004, 
Topaloglu et al. 2005, Porteus et al. 2003).  It has been shown previously that the 
introduction of a DNA double-strand break in a DNA target gene can stimulate the 
frequency of rAAV-mediated gene targeting over 100-fold (Porteus et al. 2003, Miller et 
al. 2003).  Accordingly, we chose to adapt this technique for our purposes of verifying 
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that group II intron RNPs can introduce double-strand breaks at the genomic level 
capable of stimulating the integration of rAAV-based gene targeting vectors (Porteus et 
al. 2003).  To do so, we obtained rAAV gene targeting vectors for the CCR5 gene and 
applied them to HCT116 cells along with the CCR5-targeted group II intron RNP.    
3.4.1 Designing the rAAV Targeting Vectors for the CCR5 Gene 
Designing a rAAV targeting vector basically involves the replacement of the viral 
genome of the WT AAV between the cis-acting terminal repeats with foreign DNA 
(Hirata & Russell 2000).  Removing the viral genes, specifically the rep gene, prevents 
insertion at the site-specific integration locus of wild-type AAV located on human 
chromosome 19 and allows for the insertion of new genetic cargo material to be delivered 
by the virus to the cell.  Foreign DNA inserted in place of the viral genome usually 
consists of a transgene cassette containing a promoter and polyadenylation signal most 
often totaling less than 4.7 kb in length, limited specifically by the cargo capacity of the 
encapsidated virus.  AAV vectors are directed to insert into gene-specific locations in the 
genome by DNA sequences with homology to the chromosome.  Interestingly, rAAV 
vectors can integrate site-specifically using four times less homologous sequence than 
conventional plasmid-based homologous recombination-dependent targeting vectors 
(Vasileva & Jessberger 2005).  This reduces the need for long regions of homologous 
sequence flanking the selection marker. 
To disrupt the CCR5 gene in HCT116 cells, we used two different rAAV 
targeting vectors.  The rAAV construct used in our first rAAV-based gene targeting 
experiments is described in Kohli et al. (2004), and was obtained from Bert Vogelstein.  
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The rAAV expression vector, pAAV-CCR5, is designed for expression of the viral 
genome using the accompanying Stratagene vectors (Figure 3.6b). The original intent for 
this vector in the Vogelstein lab was to re-create the CCR5 '32 deletion identified in 
certain human populations that have been shown to naturally exhibit resistance to HIV-1 
infection (Figure 3.6b).  By chance, the 5’ homology arm (HA) of pAAV-CCR5 overlaps 
the target site for the CCR5-targeted group II intron RNP (Figure 3.6b).  Specifically, the 
5’ HA begins 596 bp upstream of our group II intron insertion site and extends 231 bp 
downstream of it (Figure 3.6b).  The 3’ HA begins 277 bp downstream of our target site 
and extends 1184 bp downstream of it (Figure 3.6b).  Replacing the viral genome are the 
homology arms that flank a gene conferring resistance to neomycin (G418) linked in 
tandem to a gene conferring zeomycin resistance.  The neoR gene is driven by the 
phosphogycerate kinase (PGK) promoter and also contains a polyadenylation signal (pA) 
(Figure 3.6b).  Use of a selection marker cassette containing an exogenous promoter 
offered a much-improved opportunity for expression of the selection marker than when 
depending upon the endogenous promoter from the CCR5 gene.  The zeomycin-
resistance gene derived from pZeoSV contains an EM7 promoter and is used for selection 
in bacterial cells.  Also present in the targeting vector upstream of the neoR gene and 
downstream of the zeomycin resistance gene are loxP sequences for removal of the 
antibiotic resistance genes after genomic integration (Kohli et al. 2004).  Because this 
rAAV gene targeting vector is designed to integrate in the region of the CCR5 gene 
containing our target site, we had reason to believe that a double-strand break introduced 
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by the CCR5-targeted group II intron RNP could stimulate incorporation of the vector at 
the target site.   
 Moehle et al. (2006) demonstrated that conventional plasmid-based targeting 
vectors containing 750 bp of homologous sequence directly flanking an artificially 
induced DNA double-strand break is sufficient to deliver up to 7.7 kb of exogenous DNA 
into the genome.  With this in mind, we designed a second rAAV vector that fit these 
parameters.  Based on the results presented in Moehle et al. (2006), we designed the 
vector to contain 750 bp of homologous sequence on either side of the CCR5-targeted 
group II intron cleavage site (Figure 3.6c).  Carlo Rago from the Vogelstein lab 
constructed the second rAAV vector (pAAV-CCR5t) using previously described methods 
(Kohli et al. 2004, Rago et al. 2007).  The homology arms flank a selection marker 
cassette similar but not identical to the cassette previously described for pAAV-CCR5 
(Figure 3.6b).  In the newly designed rAAV vector, a SV40 promoter rather than a PGK 
promoter drives expression of the neoR gene (Figure 3.6c).  A multi-cloning site (MCS) 
was also added upstream of the SV40 promoter and downstream of the loxP sequence.  
Although these differences are significant at the sequence level, the selection cassette in 
pAAV-CCR5t is expected to perform similarly to that for the pAAV-CCR5 vector. 
3.4.2 RNP-Stimulated Integration of a Recombinant AAV Vector 
The method of targeting the CCR5 gene by group II intron RNP-stimulated 
homologous recombination in conjunction with the rAAV vector requires adaptation of 
the conventional rAAV gene targeting approach (Rago et al. 2007).  Because these 
experiments were performed using HCT116 cells, a commonly used cell line for rAAV 
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experiments, we were able to modify existing protocols established in the Vogelstein lab 
for targeting these cells with rAAV alone (Rago et al. 2007).  The essential difference in 
the targeting experiment is the introduction of the group II intron RNP.  Addition of the 
RNP to the targeting process required modifications to the protocol that allowed for 
delivery of the RNP subsequent to transduction with the rAAV virus.  The most 
established method in our lab for delivering the RNP to the cells is by electroporation, as 
previously described.  For HCT116, there was no established electroporation protocol for 
the delivery of RNPs so I tested electroporation conditions previously utilized for 
HEK293 cells and K562 cells (Table 3.1).   
Briefly, HCT116 cells were grown in T-25 cell culture flasks to approximately 
60-80% confluency in McCoy’s 5A cell culture medium.  All the samples were treated 
identically leading up to the experiment.  Once the cells reached the desired confluency, 
the medium was removed and the cells were washed with PBS.  Four different types of 
samples were included in a typical experiment.  Sample-type 1 received no virus and no 
RNP.  Sample-type 2 received the virus but was not treated with RNP, nor was this 
sample electroporated.  Sample-type 3 received virus and received an electroporation 
pulse without any RNP.  Sample-type 4 was treated with virus and electroporated with 
the CCR5-targeted RNP.  Variations on sample 4 usually included differing amounts of 
RNP and/or different electroporation conditions.   
As described in Rago et al. (2007), the rAAV virus was added drop-wise to the 
surface of the cells in the T-25 flask.  Immediately following the addition of the virus, the 
cells were covered with 2.5 mL of Opti-MEM (Invitrogen).  The cells were incubated 
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with the virus for 2 hours at 37ºC.  After incubation with the virus, the cells were treated 
according to prescribed conditions with or without the group II intron RNP and with or 
without electroporation.  Accordingly, sample 1 usually served as the negative control 
receiving no virus, no RNP, and no electroporation.  For this sample, cells were simply 
washed with PBS prior to adding 4 mL of complete growth medium and incubation at 
37ºC.  Sample 2, the positive control sample for viral targeting, received 4 mL of 
complete growth medium after viral transduction and incubation at 37ºC.  Samples that 
were designated to receive RNP were rinsed with PBS and trypsinized to release them 
into suspension.  The cells were harvested by centrifugation and resuspended in complete 
medium to neutralize the trypsin.  Cells from samples 3 and 4 were washed 3 times with 
FBS (-) medium.  The cells were counted and subsequently diluted to 1.25 x 106 
cells/mL.  Next, aliquots of 800 µL of the cell suspension were transferred to Eppendorf 
tubes corresponding to each sample 3 and 4.  Cells for sample 3 were transferred to the 
electroporation cuvette to be electroporated according to established conditions (Table 
3.1).  A select amount of RNP, usually 10-50 µg, was added to sample 4 and the cells 
were electroporated, as described above.  Following electroporation, the cells were 
immediately transferred to a T-25 flask containing 2.5 mL of FBS (-) medium.  All the 
samples were incubated at 37ºC for 72 hours.  After 72 hours, each flask of cells was 
trypsinized.  The cells were collected by centrifugation and resuspended in fresh 
complete McCoy’s 5A medium containing 400 µg/mL Geneticin for antibiotic selection 
of resistant cells.  The cells were diluted to 105 cells/mL and 100 µL (104 cells total) of 
each sample was distributed to each well of 96-well plates.  The plates were wrapped in 
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plastic wrap and incubated for 14 days at 37ºC.  After 14 days, wells containing grown 
cells were trypsinized and the antibiotic-resistant cells were transferred to a second 96-
well plate such that each well contained cells resistant to antibiotic selection.  Once the 
cell growth in the new plates reached approximately 80% confluency, genomic DNA was 
extracted using a 96-well Blood Kit (QIAgen).  DNA concentration was determined 
using a nanodrop and the eluted DNA was used as the template for PCR screening for 
gene targeting events.   
3.4.3 PCR Analysis of RNP-Stimulated Targeting by Recombinant AAV at the 
CCR5 Target Site 
 
The PCR-based strategy for identifying the cell clones that contain recombinant 
alleles involved the amplification of a DNA fragment using a primer that annealed within 
the NeoR gene and a second primer that anneals in the CCR5 gene outside the homology 
region of the rAAV vector (Figure 3.12).  The resulting amplicon of known size spans the 
entire HA and will only be amplified when the marker is integrated at the target site.  
PCRs were carried out in 20 µL reaction volumes using modified parameters from Rago 
et al. (2007).  The PCR products were separated by gel electrophoresis and lanes were 
examined for the presence or absence of a PCR product of the correct size.  Because the 
homology arms used for targeting were ~900 bp, the complete amplicon, which consisted 
of the homology arm and a portion of the neoR expression cassette totaled 1.6 kb (Figure 
3.12b).  Presence of the correct sized PCR product indicated that the specific targeting 
event had occurred at the CCR5 target site.  PCR products were sequenced for 
confirmation. 
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The targeting experiment in which pAAV-CCR5 was the plasmid source for 
production of the rAAV vector was expected to be sub-optimal for observing a 
stimulatory effect of the CCR5-targeted intron on integration, because the 5’ homology 
arm overlapped the double-strand cleavage site rather than flanking it.  Despite these 
circumstances, I was able to detect targeting events with a high degree of site-specific 
integration among all samples that received the virus.  Figure 3.12c summarizes the 
results of the targeting for each of the 4 samples in the pAAV-CCR5 targeting 
experiment.  A typical PCR screening panel is depicted in Figure 3.12b.  As can be seen 
in Figure 3.12c, samples receiving the electroporation pulse with and without the RNP 
exhibited a higher targeting efficiency than those that did not receive the pulse.  It has 
been found previously that the ratio of targeted to random integrations using double-
stranded DNA targeting vectors can be increased based on the voltage and capacitance 
used during electroporation (Mohn & Koller 1995).  While electroporation alone did 
increase the targeting efficiency 1.7-fold above that observed for the non-electroporated 
sample (from 36% to 64%), cells that received the CCR5-targeted RNP (50 µg) showed 
an even higher targeting efficiency (81.25%), 2.2-fold above that observed for the non-
electroporated sample (Figure 3.12c).  The additional increase in targeting efficiency 
associated with the inclusion of the group II intron RNP in the targeting experiment 
suggests that the RNP may have an enhancing effect on rAAV integration.  We would 
expect that double-strand cleavage at the target site by the group II intron RNP would 
stimulate the integration of the rAAV, however we had no way of predicting the extent of 
the stimulation.  In this case, it might be argued that the group II intron RNP provides an 
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increase of 120% over the targeting efficiency for cells that received the virus without 
electroporation or the RNP.  Further, we observed an increased targeting efficiency 27% 
above that for the electroporated cells that received the virus but no RNP (Figure 3.12c).  
Of course, these results can be further scrutinized and it is recommended that these 
experiments be repeated.  However, since this particular rAAV vector is believed to be 
sub-optimal, it was not in our interest to pursue these experiments further.   
In another targeting experiment we used the customized rAAV vector, produced 
from pAAV-CCR5t, which was designed in the optimal configuration for integration at 
the target site compatible with the CCR5-targeted group II intron such that the homology 
arms directly flank the double-strand cleavage site (Moehle et al 2007) (Figure 3.6c).  
Figure 3.12d summarizes the results of this experiment in which two different amounts of 
RNP were applied in conjunction with two different electroporation conditions for the 
delivery of the RNP.  Once again the samples receiving the electroporation pulse had 
fewer colonies than the samples that did not receive the pulse.  Also, cells electroporated 
with the higher amounts of RNP (18 µg) showed increased targeting efficiencies (100% 
and 93.3%) over those that received no RNP or 5 mg of RNP (83.3% and 75%, 
respectively) (Figure 3.12).  In this experiment, two different amounts of RNP were 
delivered using two different electroporation conditions.  Figure 3.12d shows that the 
samples receiving a lesser amount RNP had lower targeting efficiencies.  Further, the 
sample that was treated with the higher amount of RNP and electroporation condition 1 
exhibited a higher targeting efficiency than the sample that received the same amount of 
RNP and electroporation condition 2.  This suggests that electroporation condition 1 
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more efficiently delivered the RNP than electroporation condition 2.  As shown in Figure 
3.12c, both samples containing the higher amount of RNP, regardless of the 
electroporation condition, showed a higher targeting efficiency than the sample that 
received no CCR5-targeted RNP.  Similar to the previous experiment, the targeting 
results suggest that electroporation of the HCT116 cells with the RNP has a stimulatory 
effect on the integration of the rAAV, presumably due to double-strand cleavage by the 
RNP at the target site.   
3.5 Discussion 
The need for new gene-targeting technologies is clear.  The current gene targeting 
tool kit is rife with weak and troubled technologies.  Even the most recently developed 
and commonly used methodologies, such as siRNAs and zinc-finger nucleases, have 
significant drawbacks that limit their versatility.  For siRNAs, the need to constantly 
replenish the RNAs requires plasmid DNA to be transfected into the cells, which can 
result in uncontrollable integration, presenting potentially dangerous repercussions 
(Ledwith et al. 2000, Robertson 1994).  Such risks of random integrations are the reason 
some gene therapy programs have been discontinued (Hacein-Bey-Abina et al. 2003).  As 
for zinc-finger nucleases, their value has yet to be determined, largely because the need 
for protein engineering has limited the production of a broad selection of targeted 
nucleases.  The number of genes that have been targeted using ZFNs is disappointing 
given the amount of time that has passed since the technology was shown to be effective 
for gene targeting.  Until the engineering of zinc-finger nucleases becomes more 
simplified and more productive, the uses of ZFNs will be limited.     
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The absence of a perfect gene-targeting method highlights the necessity for 
developing new technologies like that proposed here for group II introns.  Advancing 
group II introns toward gene targeting will provide a new tool with a broad range of 
biochemical activities that can be exploited for a variety of genetic engineering 
applications.  The ability to deliver genes, disrupt genes, and act as site-specific 
endonucleases makes group II introns a powerful alternative to existing technologies.  
The fact that this single particle can carry out so many different processes makes it a 
potentially invaluable option with seemingly infinite applications.   
In this chapter, I provide data to show that group II introns should be considered a 
legitimate prospect for future gene targeting in eukaryotic cells.  Obviously, a significant 
amount of development remains to be done, but based on the results presented here, 
group II introns have potential to be used in at least two different ways to disrupt target 
genes.  First, I present evidence that group II introns have the ability to integrate into the 
genome of cultured mammalian cells.  Using electroporation, group II introns were 
delivered to K562 cells.  From these cells, PCR amplified a fragment corresponding to 
the 3’ integration junction of the CCR5-targeted intron at the CCR5 target site.  
Integration at a single-copy endogenous gene has not been described previously.  
Repeating these experiments and determining the optimal conditions for single copy 
genes would be a huge leap forward in our gene targeting capabilities.  Second, I used 
two different types of gene targeting vectors designed to disrupt the CCR5 gene by 
homologous recombination to show that a group II intron could stimulate their integration 
and enhance the targetability of these vectors.  A linearized plasmid DNA designed to 
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integrate into the CCR5 gene was delivered with and without the CCR5-targeted RNP.  
Only those cells that received both the targeting vector and the RNP successfully 
integrated the donor DNA.  PCR confirmed the integration of the vector at the target site.  
The apparent RNP dependence for the integration of the donor DNA was a promising 
result and provided a novel protocol for using the RNP in eukaryotic cells.  To reinforce 
the results demonstrated using the double-stranded DNA targeting vector, I obtained two 
different rAAV vectors designed to disrupt the CCR5 gene.  The rAAV vector utilizes the 
single-stranded genome of the virus to integrate into the genome in a site-specific manner 
based on sequences that have homology to the target site.  The two rAAV constructs used 
in these studies differed such that they were designed to integrate at different sites in the 
CCR5 gene.  The sites were less than 300 bp apart and the homology arms of the vectors 
either overlapped or flanked the cleavage site for the group II intron RNP.  For both 
vectors, it was determined that the group II intron RNP could stimulate the integration of 
the recombinant viral genome.  We conclude that the stimulation of homologous 
recombination is likely the result of double-strand breaks created by the RNP.  These 
results are consistent with other experiments that show that double-strand breaks can 
stimulate the integration of rAAV, provided they occur in proximity to the rAAV target 
sequence (Porteus et al. 2003, Miller et al. 2003).   
While I have high confidence that group II introns stimulated the integration of 
both the double-stranded DNA and the rAAV gene targeting vectors, the activity of the 
RNP appears to be inefficient when compared to similar experiments performed using 
other types of site-specific endonucleases (Moehle et al. 2007, Porteus et al. 2003).  
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Whereas ZFNs were shown to stimulate the integration of double-stranded DNA by as 
much as 250-fold and rAAV by 100- to 300-fold, group II introns were only able to do so 
by approximately 0.25- to 2-fold (Moehle et al. 2007, Porteus et al. 2003).  The 
explanation for the inefficient activity of group II introns in eukaryotic cells has been 
discussed in previous chapters.  Primarily, the intracellular concentration of Mg2+ limits 
the activity of the RNP.  Based on in vitro experiments, group II introns function 
maximally at 10 mM Mg2+ while mammalian intracellular free Mg2+ levels are usually 
between 0.5 mM and 1.2 mM (Romani & Scarpa 2000, Romani & Maguire 2002).  
Further, plasmid targeting in zebrafish and Drosophila embryos and Xenopus oocytes 
was also shown to require intracellular Mg2+ concentrations that approached 10 mM for 
optimal intron integration (Mastroianni et al. 2008).  Unfortunately, increasing the 
intracellular Mg2+ levels in mammalian cells is difficult because mammalian intracellular 
Mg2+ concentrations are highly regulated and large increases in Mg2+ concentrations 
would likely result in significant cell death (Romani & Scarpa 2000, Patel et al. 1994, 
Hartwig 2001).  Alternatives to addressing the Mg2+ limitations might include 
engineering a group II intron or identifying a naturally occurring retargetable group II 
intron that functions at low Mg2+.   
It is also likely that the inefficient targeting observed in the experiments presented 
here is due to inefficient delivery of the RNP by electroporation.  Developing an assay 
that tests the effective delivery of the RNP or repeating the experiments presented here 
using a broad range of electroporation conditions could overcome this problem.  Other 
possibilities for improving the delivery of the RNP include in vivo expression of the 
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group II intron.  Presumably, producing high levels of the group II intron in the cell 
through expression will increase the probability of targeting.  However, as previously 
mentioned, when expressing the intron in vivo, one will have to address the issue of sub-
optimal Mg2+ for both the forward splicing and reverse splicing reactions.  Although 
preliminary data in our lab suggests that LtrA-dependent forward splicing occurs in 
mammalian cells when both the protein and the intron RNA are expressed from a 
plasmid, the splicing efficiencies were found to be low.  Again, this should refocus 
optimization efforts on addressing the problem of low intracellular Mg2+ concentrations. 
Another limiting factor for group II intron gene targeting in mammalian cells that 
may reduce the efficiency of gene targeting is nuclear localization.  While preliminary 
data performed by others and the data presented here suggest that electroporated group II 
introns are able to localize to the nucleus of mammalian cells to find their targets, closer 
examination will likely reveal that the efficiency of nuclear localization is low.  
Electroporation is effective for delivering nucleic acids and RNPs to cells, however 
reaching the nucleus is much less efficient than reaching the cytoplasm and often requires 
active transport (Favard et al. 2007, Lechardeur & Lukacs 2002, Golzio et al. 2002).  
Further, despite the fact that others in our lab have shown through expression analysis 
that attaching a nuclear localization signal to LtrA drives the protein component of the 
RNP to the nucleus, it is unclear whether the protein is delivered with or without the 
intron RNA.  Testing RNP delivery using equipment such as the Nucleofector (Amaxa), 
which is designed to deliver nucleic acids specifically to the nucleus with higher 
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efficiencies than standard electroporation devices, may assist in addressing the issue of 
nuclear localization (Martinet et al. 2003).   
The experiments described here address specific limitations of experiments 
previously performed in our lab.  Some of the drawbacks of previous experiments 
performed in our lab include: 1) the lack of a positive control for experimental 
comparisons, 2) the inefficiencies associated with the group II intron targeting activity in 
eukaryotic cells, especially regarding single-copy target sites, and 3) the inability to 
enrich for and isolate living cells containing group II intron-based targeting events.  I set 
out to design experiments that would address each of these issues.  Use of rAAV as a 
gene-targeting vector with measurable integration efficiency offered a positive control 
level of targeting upon which the enhancement effects of the group II intron can be 
quantified.  In addition, the goal of enriching and isolating cells containing gene-targeting 
events was accomplished using both the integration of the linearized double-stranded 
donor DNA and the integration of the rAAV targeting vectors, which contained selection 
markers.  Of the two types of targeting vectors, rAAV proved to be a more useful tool for 
determining the effects of group II introns on integration because rAAV integrates with a 
quantifiable frequency.  Increases in targeting efficiency may be attributed to the group II 
intron.  Thus, rAAV is more amenable to the necessary optimization experiments that 
will need to be performed in the future to learn more about the targeting behaviors of the 
group II intron in vivo.  It is my great hope that the advancements toward genome 
targeting described here will be influential in designing future experiments to improve the 
targeting efficiency of group II introns in eukaryotic cells.!
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Figure 3.1 Target Site for the CCR5-Targeted Group II Intron  
 
(a) Alignment of the intron EBS1, EBS2 and ! sequences with the DNA target 
site sequences (IBS1, IBS2 and !’) in the human genomic sequence for the CCR5 gene.  
The CCR5-targeted intron was among the first customized introns to be designed using 
data gathered from a library of randomized DNA target sites (IBS and !’) (Guo et al., 
2001).  (b) Among several introns designed to insert into the CCR5 gene, CCR(332s) had 
the highest mobility (53%).  The intron inserts into the CCR5 gene 332 nucleotides 
downstream of the start codon.  Adapted from Guo et al. (2001).  (c) The insertion site 










































particles were prepared by combining purified LtrA protein and excised lariat intron 
RNA obtained by in vitro self-splicing of the CCR5-targeted Ll.LtrB intron RNA 
(pACD2-CCR5(332s)/NheI in vitro transcript).  The spliced RNA included in the RNP 
reconstitution contains a mixture of RNAs, 60-70% of which is intron lariat, while the 
remaining 30-40% consists of precursor RNA and splicing products including ligated 
exons and linear intron RNA.  Therefore, when determining the RNA concentration by 
O.D.260, it is difficult to specify the exact amount of protein to include in the RNP 
reconstitution.  The TPRT results shown here reflect the in vitro targeting activity for 
RNPs reconstituted with increasing amounts of LtrA (20 nM, lane 8, 40 nM, lane 7, 60 
nM, lane 6, 80 nM, lane 5, 120 nM, lane 4, and 160 nM, lane 3) and a constant 
concentration (20 nM) of spliced intron RNA (83 µg).  The optimal targeting activity 
Lane 6 corresponded to a ratio of 60 nM protein to 20 nM RNA which is a 3:1 ratio.!
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pBRR3-CCR5 + CCR5 332s RNP 
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Targeting reactions were carried out by incubating 1 µg of the unlabeled plasmid 
DNA, pBRR3-CCR5, (Lane 1) or specified amounts (0.5 ng, Lane 2, 5.0 ng, Lane 3, 50 
ng, Lane 4) of genomic DNA with 1 µg of reconstituted CCR5-targeted RNP particles in 
20 µL of TPRT buffer [10 mM KCl, 10 mM MgCl2, and 50 mM Tris-HCl (pH 7.5)] 
containing dATP, dGTP, dTTP and dCTP (0.2 mM each) (Invitrogen).  The reactions 
were initiated by addition of the RNP particles, and the mixtures were incubated for 30 
min at 37°C.  Reactions were stopped by phenol-CIA extraction.  The DNA was ethanol 
precipitated from the supernatant.  The DNA pellet was resuspended in 10-20 µL of TE 
[10 mM Tris-Cl, pH 7.5, 1 mM EDTA] and used as the DNA template for PCR.  (a) For 
plasmid targeting, the 3’-integration junction was amplified by PCR using the intron-
specific primer, ltrB 816s (p1), and a plasmid-specific primer located downstream of the 
target site, Seq pBRR MCS+RR (p2).  The expected size of the amplicon was 586 bp.  
For genomic DNA targeting, the 3’-integration junction was amplified by PCR with the 
intron-specific primer, ltrB 816s (p1), and a CCR5-specific primer located downstream of 
the target site, CCR5 +367-+340 (p3).  The expected size of the amplicon was ~492 bp.  
(b) Successful amplification across the 3’ junction suggests that the intron has correctly 
inserted at its target site and the intron RNA is reverse transcribed at least up to the 
annealing point for the PCR primer.  The 586-bp PCR product corresponding to the 3’ 
junction was readily amplified from the plasmid targeting experiment that was performed 
parallel to the genome targeting experiment.  The 492-bp amplicon corresponding to the 
3’ junction for genomic DNA targeting verified that the CCR5 RNP could find its target 
site even within a more complex genetic environment.  Based on the amounts of genomic 
DNA used in the cold TPRT reactions (50 ng, 5.0 ng and 0.5 ng), in vitro targeting of the 
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The electroporation conditions used to deliver group II introns to three different cell lines 
are described in this table.  The conditions for HEK293 cells were empirically determined 
in our lab.  The conditions for K562 cells were based on Bio-rad electroprotocols for 
delivery of DNA.  HCT116 cells were electroporated using the protocols for both 












































Figure 3.4 Direct Integration of a Group II Intron at the CCR5 Target Site 
 
The CCR5-targeted RNP was delivered to K562 cells to disrupt the CCR5 gene 
by direct integration.  K562 cells were grown in IMDM (Invitrogen) with 10% FBS and 
penicillin-streptomycin (Invitrogen) to 1 $ 106 cells/mL.  Cells were harvested by 
centrifugation and washed 3 times with FBS (-) IMDM.  The cell pellet was resuspended 
in FBS (-) IMDM to a density of 6.25 $ 106 cells/mL or 6.25 $ 105 cells/mL.  5 $ 106 
cells (800 %L) or 5 $ 105 cells (800 %L) were transferred to 1.5 mL-microcentrifuge tubes 
and combined with specified amounts (10 %g or 20 %g) of CCR5-targeted RNPs at room 
temperature.  2 M MgCl2 was added to some samples to a final concentration of 25 mM.  
The cells were electroporated using a Gene Pulser II electroporation system (Bio-Rad).  
After electroporation, the cells were incubated at either room temperature or 37°C for 15 
min and transferred to a T-25 flask containing 10 mL of IMDM complete medium.  
Genomic DNA was extracted using the GenElute Mammalian Genomic DNA Miniprep 
Kit (Sigma).  Intron integrations were amplified by PCR to detect the 3’-integration 
junction.  The primary PCR used the intron-specific primer, ltrB 816s, and a CCR5-
specific primer, CCR5 +367-+340.  Primary PCR products were purified using the 
QIAquick PCR Purification Kit (Qiagen).  The purified PCR products served as the 
template for nested PCR using primers, ltrB 890s and CCR5 +156-+140.  The results are 
shown in the 1% agarose gel above in which lanes 1-8 correspond to the following 
samples: Lane 1, No RNP + 25 mM MgCl2, 5x10
6 cells, 37°C recovery; Lane 2, 10 µg 
RNP, 5x106 cells, 37°C recovery, No electroporation pulse; Lane 3, 10 µg RNP, 5x106 
cells, 37°C recovery; Lane 4, 10 µg RNP, 5x106 cells, 25°C recovery; Lane 5, 10 µg 
RNP, 5x105 cells, 37°C recovery; Lane 6, 20 µg RNP, 5x106 cells, 37°C recovery; Lane 
7, 10 µg RNP + 25 mM MgCl2, 5x10
6 cells, 37°C recovery; and Lane 8, No RNP, 5x106 
cells, 37°C recovery.  Intron integration was detected in a single sample (Lane 6) in 
which 20 µg of RNP was delivered to the cells. 
RNP (µg)  
MgCl2 (mM) 
Rec Temp 
  -         10          10         10         10         20          10           -  
25          -             -            -           -    -            25          - 














Figure 3.5 Configurations for Plasmid-Based Gene Targeting Vectors 
 
 Donor DNA molecules fall into one of two categories.  Either they are classified 
as “ends-out” or “ends-in” recombination constructs.  Ends-out constructs are also known 
as replacement constructs because they can replace genomic sequences while inserting 
new sequence at the site of integration.  The experiments performed here employ the 
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Figure 3.6 Donor DNA Constructs for Targeting CCR5 
 
(a) The pick-up fragment (PUF) donor DNA, pCCR5-PUF2, was designed to 
incorporate at the CCR5 gene by homologous recombination (HR) in K562 cells.  The 
design of the PUF construct is based on standard HR DNA constructs used in classical 
gene targeting experiments in which regions of sequence homology flanking the desired 
insertion site are located on either side of a selection marker (Doetschman, 1988, 
Bronson, 1994).  Two regions of homology were amplified by PCR from the CCR5 gene; 
the first beginning 25 bp 5’ of the target site and extending 2.2 kb upstream, including a 
portion of intron 2 and exon 4, and a second fragment beginning 15 bp 3’ of the target 
site and extending 4.1 kb downstream, consisting of a portion of exon 4 and intron 3.   
The 40 bp directly flanking the target site were omitted from the construct in order to 
prevent the RNP from targeting the donor DNA molecule prior to or following insertion.  
An ATG (-) blasticidin resistance gene was cloned in frame with the upstream coding 
sequence of exon 4 from the CCR5 gene.  Therefore, expression of the blasticidin-
resistance gene would necessarily be driven by endogenous transcription from the CCR5 
promoter upon integration.  Successful targeting events could then be selected based on 
blasticidin resistance.  The donor DNA was constructed in a pUC19 plasmid backbone 
such that linearization (MluI digestion) of the vector was necessary for the targeting 
vector to take on an “ends-out” arrangement when aligned along the targeted 
chromosome.  Upon integration, the blasticidin selection cassette and the pUC19 vector 
backbone replace the 40-bp sequence corresponding to the group II intron recognition site 
upon integration.   
(b) To disrupt the CCR5 gene in HCT116 cells, we used two different rAAV 
targeting vectors.  pAAV-CCR5, obtained from Bert Vogelstein, was designed to re-
create the well-documented human CCR5 '32 deletion which provides resistance to HIV 
infection.  The 5’ homology arm (HA) of pAAV-CCR5 overlaps the target site for the 
CCR5-targeted group II intron RNP.  Specifically, the 5’ HA begins 596 bp upstream of 
the group II intron insertion site and extends 231 bp downstream of it.  The 3’ HA begins 
277 bp downstream of the intron target site and extends 1184 bp downstream of the target 
site.  The homology arms flank a gene conferring resistance to neomycin (G418) linked 
in tandem to a gene conferring zeomycin resistance.  The neoR gene is driven by the 
phosphoglycerate kinase (PGK) promoter and also contains a polyadenylation signal 
(pA).  The zeomycin-resistance gene derived from pZeoSV contains an EM7 promoter 
and is used for selection in bacterial cells.  Also present in the targeting vector upstream 
of the neoR gene and downstream of the zeomycin-resistance gene are loxP sequences for 
removal of the antibiotic resistance genes after genomic integration (Kohli, 2004). 
(c) We designed a second rAAV vector to contain 750 bp of homologous 
sequence on either side of the CCR5-targeted group II intron cleavage site.  The 
homology arms flank a selection marker cassette similar to the cassette previously 
described for pAAV-CCR5 except a SV40 promoter rather than a PGK promoter drives 
expression of the NeoR gene.  The selection cassette in pAAV-CCR5t is expected to 
























RNPs were delivered along with the linearized pCCR5-PUF2 donor DNA to 
K562 cells by electroporation using conditions described in Table 3.1 to test for RNP-
stimulated integration of the donor DNA.  Both the donor DNA and the RNP were 
resuspended in HKM buffer [10 mM KCl, 10 mM MgCl2, and 40 mM HEPES, pH 8.0].  
Cells were suspended at 5 x 106 cells/mL in 800 µL of IMDM medium (Invitrogen).   A 
constant concentration of donor DNA (approximately 10 µg) was tested with varying 
concentrations of CCR5-targeted RNP (12.5 µg, 25 µg and 50 µg).  The RNP and DNA 
were added separately to the cell suspension prior to electroporation.   After 
electroporation, cells were transferred to a T-75 culture flask containing 50 mL of growth 
medium without FBS and incubated at 37ºC for 1 h.  After 1 h, the medium was 
exchanged, and the cells were incubated overnight in complete medium without 
selection.  After 48 hours of recovery, the selection process for gene targeting events was 
initiated by adding blasticidin (5 µg/mL) to the medium.  Five days post-electroporation, 
the concentration of blasticidin was increased to 10 µg/mL.  Cells resistant to blasticidin 
were tracked by counting live cells in each of the samples.  On day 29, cells were 
collected and either transferred to plates treated with WSC and conA to pan for live cells 
or they were used for genomic DNA extractions.  Cells used for the panning method were 
grown up into large enough clusters to pick and transfer to 96-well plates.  Genomic 
DNA extracted from the heterogenous pool of cells was used for PCR screening for PUF 
integrations.  Cells that grew in the 96-well plates were also used for genomic extractions 
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Following electroporation with the CCR5-targeted RNP and plasmid-based donor 
DNA, cells resistant to blasticidin were tracked by counting live cells in each of the 
samples.  48 hours after electroporation, selection of blasticidin resistant cells was 
initiated by adding 5 µg/mL blasticidin to the medium.  Five days post-electroporation, 
the concentration of blasticidin was increased to 10 µg/mL.  By day 11, the cells were 
experiencing significant cell death in all samples.  From day 13 until day 21 post-
electroporation, the number of live cells in all samples except the positive control (sample 
7) was greatly reduced.  The positive control sample had been transfected with a plasmid 
expressing the blasticidin resistance gene from a constitutive promoter, therefore it was 
expected to contain cells resistant to the antibiotic.  By day 26, samples that received both 
the RNP and the donor DNA (Samples 4-6) began to approach the number of live cells 
observed in the positive control.  By day 29, cells in the sample that received neither the 
donor DNA nor the RNP (Sample 1) and cells that received either the donor DNA alone 
(Sample 2) or the RNP alone (Sample 3) were entirely eliminated by blasticidin selection.  
At the same time, each of the samples that received both the RNP and the donor DNA 
(Sample 4-6) reached comparable cell survival numbers to those of the positive control 
(Sample 7).  On day 29, samples containing live cells (sample 4-7) were collected and 
transferred to 100 mm plates for panning selection for live cells and a portion of each 
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Figure 3.9 Detection of CCR5 PUF Integration by PCR 
 
Blasticidin-resistant cells that received the CCR5-targeted RNP and donor DNA 
were screened by PCR to detect PUF integrations.  (a) A schematic diagram showing the 
PUF and the insertion product at the CCR5 target site.  Primers designed to anneal inside 
the blasticidin resistance gene and at successively increasing distances from the insertion 
site are shown as arrows above the insertion product (p1-p10).  Primers, p1 (CCR5 exon 
1) and p2 (CCR5 exon 1b), were designed to anneal upstream of the 5’-homology region.  
Primers, p9 (Blasticidin 2 anti) and p10 (Blasticidin 1 anti), were designed to anneal 
within the blasticidin-resistance gene.  PCR using primer sets, p1 and p10 and p2 and p9 
allowed for nested PCR of the insertion event at the CCR5 target site.  (b) Nested PCR 
products using primers p2 and p9 resulted in amplification of a non-specific band in 
sample 4 (Lane 5), sample 5 (Lane 4), sample 6 (Lane 3) and sample 8 (Lane 2) with a 
streak of non-specific amplification in the lane containing the PCR products from sample 
6 (Lane 3).  Closer inspection revealed a faint band corresponding to a 2.6-kb PCR 
product in the lane for sample 6 (Lane 3).  This led to additional PCR analysis for sample 
6.  (c) Primers positioned within the CCR5 gene at successively increasing distances 
upstream of the integration site (p3, p4, p5, p6 and p7) were used in combination with the 
anti-parallel blasticidin resistance gene primer (p10, Blasticidin 1 anti) to amplify PCR 
products ranging from 503 bp to 2,601 bp.  The expected sizes of the PCR products when 
using primer p10 (Blasticidin 1 anti) with the CCR5 primers are as follows: p7, CCR5 
3639-3660 (503 bp product), p6, CCR5 3117-3136 (1,025 bp product), p5, CCR5 2548-
2570 (1,594 bp product), p4, CCR5 2098-2121 (2,044 bp product), p3, CCR5 1561-1585 
MluI (2581 bp product) and p1, CCR5 exon 1 (2,601 bp product corresponding to PUF 
insertion).  Asterisks mark each of the amplification products on the gel (c).  While each 
of the smaller PCR products could be amplified from randomly integrated donor DNA, 
the 2.6-kb fragment could only be amplified if the donor DNA integrated at the target site 
(Lane 2).  (d) The primary PCR product (Lane 1) and the nested PCR product (Lane 2) 
are shown to be 2,601 and 2,479 bp, respectively.  The nested PCR product was 

































(a) To confirm that the blasticidin resistance gene was present in each of the 
samples containing blasticidin-resistant cells, PCR was performed using primers, XbaI 
Bsd –ATG and Blasticidin 1 anti, p8 and p10, according to Figure 3.9a, to amplify the 
blasticidin-resistance gene.  The BsdR gene was amplified from all the samples that 
received the donor DNA but not sample 8 which is genomic DNA from untreated K562 
cells. (b) To rule out contamination between the positive control sample 7 and samples 4, 
5 and 6, PCR was performed to amplify the blasticidin-resistance gene along with the 
CMV promoter using primers, MluI CMV 5’ sense and Blasticidin 1 anti.  Since MluI 
CMV 5’ sense anneals in the promoter sequence from pCMV/Bsd it should only amplify 
a product with the expression plasmid is present.  Lane 4 shows the amplification product 
from pCMV/Bsd.  Based on these results, none of the other samples contains the plasmid.  
(c) RNA was extracted from samples 6 and 7 for RT-PCR using the RNAqueous 4PCR 
Kit (Ambion), according to manufacturer’s instructions.  cDNAs were generated using 
the primer, Blasticidin 1 anti, and the Superscript II RT Kit (Invitrogen).  The cDNAs 
generated from sample 6 and sample 7 with and without RT were used as templates for 
PCR.  The BsdR ORF was amplified using primers, XbaI BSD –ATG and Blasticidin 2 
anti.  Lane 1 and Lane 3 contain the PCR product corresponding to expression of the 
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(a) Southern blot strategy to confirm the integration at the CCR5 target site.  This 
strategy involved the use of two DNA probes.  Probe 1 was designed to anneal to the 
CCR5 genomic sequence just upstream of the 5’ end of the 5’ homology arm.  Probe 2 
was designed to anneal to the blasticidin-resistance gene.  Genomic DNA extracted from 
cells of sample 6 was to be digested with AflII.  The genomic DNA from non-targeted 
cells would result in a 5.5-kb DNA fragment, while successful integration would yield a 
DNA fragment 8.7 kb in length.  The results of the Southern blot were complicated by the 
fact that the genomic DNA of sample 6 was extracted from a heterogeneous pool of cells 
collected prior to panning for isolated antibiotic-resistant cells.  (b) When blotting against 
genomic DNA from sample 4, sample 6 and untreated K562 cells with the probe 
designed to anneal to the CCR5 gene just upstream of the targeting event, a band 
corresponding to the expected size of the integrated targeting vector was not detectable.  
The only band that was present in the Southern blot corresponded to the wild-type 
fragment.  (c) Using the probe designed to anneal to the blasticidin resistance gene would 
verify the presence of the blasticidin ORF in the genomic DNA and offer another 
opportunity to confirm integration of the donor DNA.  The Southern blot yielded a single 
band in each lane containing genomic DNA from blasticidin-resistant cells.   
Unfortunately, the single band was approximately 9 kb and was indistinguishable from 
the expected sized band for the linearized vector alone, which, albeit unlikely, may be 






















































Figure 3.12 The CCR5-Targeted Group II Intron RNP Stimulates Integration of a rAAV 
Gene Targeting Vector at the CCR5 Locus 
 
(a) PCR strategy to detect rAAV integration at the CCR5 target site.  The PCR-
based strategy for identifying cell clones that contain recombinant alleles involved the 
amplification of a DNA fragment using a primer that annealed in the CCR5 gene outside 
the homology region of the rAAV vector (p1) and a second primer that anneals within the 
NeoR gene (p2).  The resulting amplicon spans the entire HA and will only be amplified 





























































when the marker is integrated at the target site.  PCR were carried out in 20 %L reaction 
volumes using modified parameters from Rago et al. (2007).  The PCR products were 
separated by gel electrophoresis and lanes were examined for the presence or absence of 
a PCR product of the correct size.  (b) A typical PCR screening panel for rAAV targeting 
experiments.  Because the homology arms used for targeting were ~900 bp, the complete 
amplicon, which consisted of the homology arm and a portion of the neoR expression 
cassette totaled 1.6 kb.  Presence of the correct sized PCR product indicated that the 
specific targeting event had occurred at the CCR5 target site.  PCR products were 
sequenced for confirmation. (c) The results of targeting the CCR5 gene using pAAV-
CCR5 and the CCR5-targeted RNP.  Sample 1 received no virus and no RNP.  Sample 2 
received the virus but was not treated with RNP, nor was this sample electroporated.  
Sample 3 received virus and received an electroporation pulse without any RNP.  Sample 
4 was treated with virus and electroporated with 50 µg of the CCR5-targeted RNP.  
Samples 3 and 4, which received the electroporation pulse with or without the RNP, 
exhibited a higher targeting efficiency than sample 2, which did not receive the pulse.  
While electroporation alone increases the targeting efficiency 1.7-fold above that 
observed for the non-electroporated sample (from 36% to 64%), cells that received the 
CCR5-targeted RNP (50 µg) showed an even higher targeting efficiency (81.25%), 2.2-
fold above that observed for the non-electroporated sample.  The additional increase in 
targeting efficiency associated with the inclusion of the group II intron RNP in the 
targeting experiment suggests that the RNP is possibly having an enhancing effect on 
rAAV integration.  We would expect that double-strand cleavage at the target site by the 
group II intron RNP would stimulate the integration of the rAAV.  In this case, it might 
be argued that the group II intron RNP provides an increase of 120% over the targeting 
efficiency for cells that received the virus without electroporation or the RNP.  Further, 
the targeting efficiency for sample 4 is elevated by 27% above that for sample 3 which 
received the virus and the pulse but no RNP. (d) Targeting the CCR5 gene using pAAV-
CCR5t and the CCR5-targeted RNP.  Two different amounts of RNP were delivered 
using two different electroporation conditions.  Cells electroporated with the higher 
amounts of RNP (18 µg) showed increased targeting efficiencies (100% and 93.3%) over 
those that received no RNP or 5 µg of RNP (83.3% and 75%, respectively), regardless of 
the electroporation conditions used.  The sample that was treated with the higher amount 
of RNP and electroporation condition 1 exhibited a higher targeting efficiency than the 
sample that received the same amount of RNP and electroporation condition 2.  This 
suggests that electroporation condition 1 more efficiently delivered the RNP to the cells 
than electroporation condition 2.  Both samples containing the higher amount of RNP, 
regardless of the electroporation condition, show a higher targeting efficiency than the 
sample that received no CCR5-targeted RNP.  Similar to the previous experiment, the 
targeting results suggest that electroporation of the HCT116 cells with the RNP has a 
stimulatory effect on the integration of the rAAV, presumably due to double strand 




CHAPTER 4: MATERIALS AND METHODS 
 
4.1 MATERIALS AND METHODS FOR GROUP II INTRON-BASED GENE 
TARGETING IN EUKARYOTIC EMBRYOS  
 
4.1.1 Recombinant Plasmids 
pACD2 contains the 0.9-kb Ll.LtrB-#ORF intron and flanking exons cloned 
downstream of a T7lac promoter in a pACYC184-based vector with a camR gene, and has 
the LtrA ORF cloned downstream of the 3! exon (Guo et al. 2000, Karberg et al. 2001).  
The Ll.LtrB-#ORF intron contains an additional phage T7 promoter inserted in intron 
domain IV (DIV) for use in plasmid-based DNA-integration assays. 
pACD2, pACD-mitf(235s) were used for in vitro transcription of Ll.LtrB-#ORF 
intron RNAs, which are then reconstituted with purified LtrA protein to form RNPs 
(“targetrons”) for gene targeting (Guo et al. 2000).  The latter plasmid contains a Ll.LtrB-
#ORF intron in which the EBS2, EBS1 and ! sequences were modified to be 
complementary to IBS2, IBS1, and !! sequences in the DNA target site of the zebrafish 
mitf gene.  The donor plasmid used for the mitf targetron has a !! residue in the 3! exon 
complementary to the retargeted ! residue in the intron RNA for optimal RNA splicing 
(Perutka et al. 2004). 
pBRR3-ltrB, the target plasmid for intron-integration assays, contains the Ll.LtrB 
homing site (ligated exon 1 and 2 of the ltrB gene from position &178 upstream to +91 
downstream of the intron-insertion site) cloned upstream of a promoterless tetR gene in an 
AmpR pBR322-based vector (Guo et al. 2000, Karberg et al. 2001).  pBRR3-mitf and 
pBRR3-Golden ex1 are similar target plasmids in which the homing site has been altered 
! "+'!
to contain the corresponding target sites for the mitf(235s) and Golden ex1 introns, 
respectively. 
pIMP-1P, used for expression of the LtrA protein, contains the LtrA ORF cloned 
downstream of a tac promoter and &10 Shine-Dalgarno sequence in the protein-
expression vector pCYB2 (New England Biolabs, Ipswich, MA) (Saldanha et al. 1999).  
LtrA is expressed from this plasmid as a fusion protein with a C-terminal tag containing 
an intein-linked chitin-binding domain, enabling LtrA purification via a chitin-affinity 
column, followed by intein-cleavage. 
Plasmid DNAs were prepared using the QIAgen line of plasmid Miniprep and 
Midiprep Kits, unless otherwise specified. 
4.1.2 Transcription of Intron RNA and Self-Splicing Reaction 
Ll.LtrB-#ORF intron RNPs were reconstituted from in vitro-synthesized intron 
RNA and purified LtrA protein by modification of a method described previously 
(Saldanha et al. 1999). A precursor RNA containing the Ll.LtrB-#ORF intron and 
flanking exons was transcribed with phage T7 RNA polymerase (Megascript T7 Kit; 
Ambion, Austin, TX) from the appropriate pACD-based donor plasmid (see above), 
which had been linearized with NheI.  The resulting precursor RNAs containing the 
Ll.LtrB-#ORF intron and flanking exon sequences were self-spliced in 1.25 M NH4Cl, 
50 mM MgCl2, 50 mM Tris-HCl, pH 7.5 for 3 h at 37°C, then ethanol-precipitated and 
dissolved in distilled water. 
To reconstitute Ll.LtrB-#ORF RNPs, the self-spliced RNA (100 nM) was re-
natured by heating to 55°C in 10 ml of pre-splicing buffer [450 mM NaCl, 5 mM MgCl2, 
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40 mM Tris-HCl, pH 7.5] and slowly cooling to 30°C prior to addition of 200 nM of 
purified LtrA protein and further incubation for 30 min at 30°C (Saldanha et al. 1999). 
The resulting RNPs were collected by ultracentrifugation in a Beckman 50.2 Ti rotor at 
145,000 $ g for 16 h at 4°C and resuspended in 50 µl of HKM [10 mM KCl, 10 mM 
MgCl2, and 40 mM HEPES, pH 8.0]. The RNP preparations typically contain 60–70% 
intron lariat RNA with the remainder being precursor RNA plus smaller amounts of 
linear intron and ligated exons, and they typically have a concentration of 1-2 mg 
RNA/ml based on OD260. 
4.1.3 Expression and Purification of LtrA 
E. coli strains BL21(DE3) were transformed with the pImp-1P, and single 
colonies were selected on LB plates containing ampicillin (50 µg/mL).  For starter 
cultures, a single colony was inoculated into 50 mL of LB medium containing ampicillin 
(50 µg/mL), and the cultures were shaken at 225 rpm at 37°C overnight. Two mL of the 
overnight culture was then inoculated into 1 L of SOB medium containing antibiotics (50 
µg/mL ampicillin) in a 4-L Ehrlenmeyer flask and grown at 37°C in a rotary shaker (225 
rpm) for 2–4 h, until OD595 was 0.4–0.8. For induction, IPTG was added to a final 
concentration of 0.5 mM, and the incubation was continued at 25°C for 5-6 h. After 
induction, cells were collected by centrifugation in a Beckman JA-14 rotor (2,455 ( g for 
10 min at 4°C), and washed with 50 mL of ice-cold S-150 [150 mM NaCl]. The washed 
cell pellet was resuspended in 50 mL of ice-cold S-500 [500 mM NaCl, 50 mM Tris-HCl 
(pH 8.0), 0.1 mM EDTA, 0.1% NP-40], and lysozyme (Sigma, St. Louis, MO) was added 
to a final concentration of 0.1 mg/ml.  The cells were then lysed by three cycles of 
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freeze–thawing between &70°C and 25°C, followed by sonication (Branson 450 Sonifier, 
Branson Ultrasonics Inc., Danbury, CT; two 10 s bursts at amplitude 60, with at least 10 s 
between bursts).  After sonication, insoluble material was removed by centrifugation in a 
Beckman JA-14 rotor (22,095 $ g for 15 min).   
For chromatography, the cleared lysate was diluted to 80 mL with CB [0.5 M 
NaCl, 50 mM Tris-HCl (pH 8.0), 0.1 mM EDTA] and loaded on a chitin column (New 
England Biolabs; 2.5 cm $ 5 cm plastic column with a 10 mL bed volume), which had 
been washed with at least 100 mL of CB at a flow rate of 2.0 mL/min.  After loading the 
lysate, the column was washed with at least 500 mL of CB, and then with 250 mL of S-
750 [0.75 M NaCl, 50 mM Tris-HCl (pH 8.0), 0.1 mM EDTA].  After these washes, the 
LtrA&intein junction was cleaved by addition of 30 mL of 30 mM DTT in CB.  The 
column flow was stopped, and the column was incubated with the DTT overnight at 4°C.  
The released LtrA protein was then recovered by washing the column with 20 mL of CB.  
The pooled fractions were dialyzed against CB containing 50% glycerol, thereby 
concentrating the protein 4&7-fold.  Aliquots of the dialyzed protein were stored at -70°C.     
4.1.4 In vitro Target-Primed Reverse Transcription Assays 
TPRT reactions were carried out by incubating 1 %g of unlabeled target plasmid 
with 1 µg of reconstituted RNP particles in 20 µL of TPRT Buffer [10 mM KCl, 10 mM 
MgCl2, and 50 mM Tris-HCl (pH 7.5)] containing dATP, dGTP, and dCTP (0.2 mM 
each), and 20 µCi of ["-32P]dTTP (3000 Ci/mmol; New England Nuclear, Boston, MA). 
The reactions were initiated by addition of the RNP particles, and the mixtures were 
incubated for 30 min at 37°C.  Products were analyzed in a 1% agarose gel, which was 
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dried and subsequently autoradiographed with a PhosphorImager (Molecular Dynamics, 
Sunnyvale, CA). 
4.1.5 Zebrafish In Vitro Fertilization and Microinjection  
All zebrafish were reared at 28.5°C under a 14 h/10 h light/dark cycle.  Wild-type 
D. rerio strains were the AB line (Streisinger 1981).  For plasmid targeting experiments, 
sperm and eggs were collected from adult AB males and females for in vitro fertilization, 
as described (Westerfield, 2000).  For genome targeting experiments, males and females 
from the AB line were crossed with nacw2 fish to obtain heterozygous F1 progeny (Lister 
et al. 1999).  Fertilized eggs were incubated at room temperature for ~15 min prior to 
injection. For group II intron plasmid targeting assays, target plasmid (0.5 mg/ml in a 
solution containing 3.125 mM of each dNTP and specified amounts of MgCl2, with 
0.25% phenol red) and Ll.LtrB-#ORF RNPs (0.1-1.0 mg/mL with 0.25% phenol red, 10 
mM KCl, 10 mM MgCl2, and 40 mM HEPES, pH 8.0) were injected separately into 10 to 
25 one-cell embryos in Steinberg's medium (Steinberg 1957) using a pressure system 
(Picospritzer III; Parker Hannifin) with 20 psi output. The injection volumes were ~5-10 
nL. A micromanipulator (MN-151, Narishige) was used to manipulate the injection 
needles.  For genome targeting experiments, injections were performed as described 
above, except that the second injection was used to add Mg2+ without the target plasmid.  
Ll.LtrB-'ORF RNPs modified to target the mitf gene (0.05-1.0 mg/mL with 0.25% 
phenol red in HKM buffer) were injected separately from specified amounts of MgCl2 in 
0.25% phenol red in HKM buffer.  After injection of plasmid targeting reagents, the 
embryos were washed with Steinberg's medium, pooled in a single 1.5-ml Eppendorf 
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tube in 500 µl Steinberg's medium, and incubated for 1 h at 30°C, prior to plasmid DNA 
extraction and transformation of E. coli.  Embryos receiving the genome targeting 
reagents were incubated at 25°C in Steinberg’s solution for 48-72 h, which is the normal 
time frame for the appearance of melanin in melanophores.  After 48 h, the embryos were 
screened for pigment mutations. 
4.1.6 Nucleic Acid Extraction from Injected Zebrafish Embryos and Determination 
of Targeting Efficiency 
To isolate nucleic acids following injection and incubation, the embryos were 
transferred to SNET lysis buffer [20 mM Tris-HCl, pH 8.0, 5 mM EDTA, 400 mM NaCl, 
1% SDS (w/v), 400 µg/mL proteinase K (Molecular Biology Grade; Sigma-Aldrich)] for 
1 h at 55°C, and then extracted twice with phenol-CIA. Nucleic acids were precipitated 
with isopropanol and dissolved in 20–50 µL of distilled water. For plasmid targeting 
experiments, two µL of the nucleic acid preparation was electroporated into E. coli 
HMS174(DE3) F&, hsdR, recA, rifr (Novagen, EMD Chemicals, Gibbstown, NJ), and 
cells were plated at different dilutions on Luria-Bertani (LB) medium containing 
ampicillin (50 µg/mL) plus tetracycline (25 µg/mL) or the same concentration of 
ampicillin alone.  Colonies were counted after overnight incubation at 37°C, and the 
integration efficiency was calculated as the ratio of (AmpR+TetR)/AmpR colonies.  
4.1.7 PCR Detection of Site-Specific Integration of Group II Introns in Plasmid and 
Genomic Targets in Zebrafish Embryos 
For plasmid targeting, to detect intron integration by PCR for the WT RNP, the 
3’-integration junction was amplified with the intron-specific primer, ltrB 890s, and a 
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plasmid-specific primer located downstream of the target site, Seq pBRR MCS+RR.  The 
expected size of the amplicon was ~586 bp.  For plasmid targeting using mitf-targeted 
RNPs, the 5’-integration junction was PCR amplified using the intron-specific primer, 
Seq pIMP EBS1/EBS2 (1), and a primer designed to anneal in the mitf cDNA of pBRR3-
mitf upstream of the target site, mitfa/b upstream top.  The expected size for the amplicon 
was 682 bp.  For genomic targeting of the mitf gene, intron integration was screened by 
PCR amplification of the 5’-integration junction with the intron-specific primer, LtrB 
reverse bottom 1, and a mitf-specific primer located upstream of the target site, Upstream 
mitfa/b Top (1).  The expected size of the amplicon was ~500 bp.  For plasmid and 
genomic targeting, five µL of extracted DNA was used as the template for the PCR.  The 
thermocycle program was as follows: 95°C for 5 min, followed by 30 cycles of 95°C for 
30 sec, 55°C for 30 sec, 72°C for 2 min and final extension for 10 min at 72°C.  
4.1.8 Drosophila Mating and Microinjection 
The wild-type strain (Oregon-R) was grown in standard fly medium under 
standard conditions in the laboratory of Dr. David Stein.  Embryos were collected on 
apple juice agar plates with added yeast paste for collection times not exceeding 60 min.  
All procedures following egg collection were performed at 18°C.  The embryos were 
dechorionated with 50% bleach, rinsed in fresh water, adhered to a 24$30 mm glass 
cover slip, desiccated in a dish that contains Drierite and covered in 10S Voltalef Oil 
(VWR International).  Microinjection was done using filament needles with a bore size of 
~5 µm attached to an oil-filled 50-mL syringe. A micromanipulator was used to 
manipulate the injection needles. The injection volumes were ~0.3 nL. 
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The target plasmid DNA, pBRR3-ltrB, (0.3 mg/ml in dH2O) was injected into the 
posterior of the embryo, followed within 5 min by the injection of WT RNPs (1.0 
mg/ml), using different needles to avoid prior mixing. 70 embryos were injected for each 
condition and transferred to a humidified chamber for 30 min at 30°C.  The embryos 
were collected with a pipette, pooled and transferred to a tube containing 100 µL of 
phenol-CIA for extraction.  50 µL of dH2O was added to the extracted supernatant and 
the phenol-CIA extraction was repeated.  The supernatant was mixed with 500 µL of 
SNET lysis buffer (see above) for 1 h at 55°C until the embryos were completely 
solubilized and then extracted once in phenol-CIA.  Nucleic acids were precipitated with 
isopropanol and dissolved in 10 µl of distilled water.  Plasmid DNAs were then 
transformed into E. coli, as described above for zebrafish assays. 
4.1.9 Mobility Assay for the mitf Intron 
For mobility assays, E. coli HMS174(DE3) (Novagen, Madison, WI) was 
cotransformed with pACD-mitf(235s) and pBRR3-mitf plasmids and grown in LB 
medium with chloramphenicol (25 µg/mL) and ampicillin (100 µg/mL) overnight (16 to 
20 h, 37°C). A 50-µL sample of the overnight culture was inoculated into 10 mL of LB 
with the indicated antibiotics and grown to an OD595 of 0.2 to 0.3; at that point, 250 µL 
was inoculated into 5 mL of fresh LB without antibiotics and induced with 100 µM IPTG 
for 1 h at 37°C.  Cells were harvested by centrifugation, washed, resuspended in 10 mL 
of ice-cold LB, and plated on LB plus ampicillin (50 µg/mL) in the presence or absence 
of tetracycline (25 µg/mL).  Mobility frequencies were calculated as the proportion of 
(AmpR+TetR)/AmpR colonies. 
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4.2 MATERIALS AND METHODS FOR GROUP II INTRON-BASED GENE 
TARGETING IN MAMMALIAN CELL CULTURE 
 
4.2.1 Recombinant Plasmids 
pACD-CCR5(332s) is a modified version of pACD2 in which the 0.9-kb Ll.LtrB-
#ORF intron has been modified such that EBS2, EBS1 and ! sequences are 
complementary to IBS2, IBS1, and !! sequences in the DNA target site for the human 
CCR5 gene (Guo et al. 2000). The Ll.LtrB-#ORF intron contains an additional phage T7 
promoter inserted in intron domain IV (DIV) for use in plasmid-based DNA-integration 
assays.  The intron also has a !! residue in the 3! exon complementary to the retargeted ! 
residue in the intron RNA for optimal RNA splicing (Perutka et al. 2004).  pACD-
CCR5(332s) is used for in vitro transcription of Ll.LtrB-#ORF intron RNAs, which are 
then reconstituted with purified LtrA protein to form RNPs.   
pBRR3-CCR5, the target plasmid for the CCR5(332s) intron, is a modified 
version of pBRR3-ltrB that contains the CCR5 homing site cloned upstream of the 
promoterless tetR gene in an AmpR pBR322-based vector (Guo et al. 2000, Karberg et al. 
2001).  
pAAV-CCR5 and pAAV-CCR5t are modified versions of pAAV-MCS 
(Stratagene).  pAAV-MCS is  shuttle vector that contains AAV inverted terminal repeat 
(ITR) sequences necessary for AAV packaging plus NotI restriction sites useful for 
cloning the genetic cargo sequences.  pAAV-CCR5 was constructed, as described (Rago, 
2007, Kohli, 2004).  pAAV-CCR5t was constructed specifically for use with the CCR5-
targeted RNP.  For this targeting vector, homology arms were PCR amplified from 
regions directly flanking the CCR5(332s) target site.  The 5’ homology arm corresponds 
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to nucleotides at positions -750 to -1 immediately upstream of the target site.  The 3’ 
homology arm corresponds to nucleotides +1 to +750 in relation to the intron insertion 
site.  These fragments were cloned on either side of a selection marker cassette designed 
to confer resistance to neomycin (G418) and zeomycin.  Dr. Ben Park at Johns Hopkins 
University prepared the selection cassette.  Carlo Rago from the lab of Bert Vogelstein 
constructed pAAV-CCR5t, as described (Kohli et al. 2004). 
 pAAV-RC and pHelper are included with the AAV Helper-Free System 
(Stratagene).   pAAV-RC contains the AAV-2 rep and cap genes expressed from two 
different promoters encoding the replication proteins and viral capsid structural proteins, 
respectively.  pHelper contains the subset of adenovirus genes, VA, E2A and E4, which 
are necessary for high-titer AAV production in the AAV-293 cells.  
 pCMV/Bsd (Invitrogen) is a plasmid that expresses the blasticidin resistance gene 
using the bacterial EM7 promoter or the human CMV immediate-early promoter and 
contains a SV40 early polyadenylation signal sequence.  This plasmid was used as a 
positive control for blasticidin selection in gene targeting experiments and as the template 
for PCR amplification of the ATG (-) BsdR open reading frame and SV40 polyA signal 
sequence for construction of the CCR5-targeted PUF. 
4.2.2 TPRT Using CCR5-Targeted Group II Intron RNPs with Plasmid and 
Genomic DNA Targets 
K562 cells were grown in Iscove’s Modified Dulbecco’s Medium (IMDM) with 
10% FBS and penicillin/streptomycin.  Cells were harvested by centrifugation for 5 min 
at 300 ( g.  Cells were resuspended in cold IMDM, counted and diluted to 5 $ 105 cells in 
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10 mL.  Cells were again centrifuged for 5 min at 300 ( g.  Genomic DNA was extracted 
using the GenElute Mammalian Genomic DNA Miniprep Kit (Sigma), according to the 
manufacturer’s instructions.  Genomic DNA concentrations were determined using a 
Nanodrop Microvolume Spectrophotometer (Thermo Scientific).   
Targeting reactions were carried out by incubating 1 µg of the unlabeled plasmid 
DNA, pBRR3-CCR5, or specified amounts of genomic DNA with 1 µg of reconstituted 
CCR5-targeted RNP particles in 20 µL of TPRT Buffer [10 mM KCl, 10 mM MgCl2, and 
50 mM Tris-HCl (pH 7.5)] containing dATP, dGTP, dTTP and dCTP (0.2 mM each) 
(Invitrogen).  The reactions were initiated by addition of the RNP particles, and the 
mixtures were incubated for 30 min at 37°C.  After incubation, reactions were stopped by 
phenol-CIA extraction.  The supernatant was transferred to a fresh clean tube and the 
DNA was ethanol precipitated.  The DNA pellet was resuspended in 10-20 µL of TE [10 
mM Tris-Cl, pH 7.5, 1 mM EDTA]. 
 For in vitro plasmid targeting, to detect intron integration by PCR, the 3’-
integration junction was amplified with the intron-specific primer, ltrB 816s, and a 
plasmid-specific primer located downstream of the target site, Seq pBRR MCS+RR.  The 
expected size of the amplicon was 586 bp.  To detect genomic DNA targeting, the 3’-
integration junction was amplified by PCR with the intron-specific primer, ltrB 816s, and 
a CCR5-specific primer located downstream of the target site, CCR5 +367-+340.  The 
expected size of the amplicon was ~492 bp.  The thermocycle program designed for use 
with Taq DNA Polymerase (New England Biolabs) was as follows: 95°C for 5 min, 
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followed by 30 cycles of 95°C for 30 sec, 60°C for 30 sec, 72°C for 2 min and final 
extension for 10 min at 72°C.  
4.2.3 Electroporation of K562 Cells with CCR5-Targeted RNPs and PCR Screening 
for Site-Specific Intron Integrations 
 K562 cells were grown in Iscove’s Modified Dulbecco’s Medium (IMDM) 
(Invitrogen) with 10% FBS and penicillin-streptomycin (Invitrogen) to 1 $ 106 cells/mL.  
Cells were harvested by centrifugation at 300 ( g for 5 min and washed 3 times with FBS 
(-) IMDM.  The cell pellet was resuspended in an appropriate volume of FBS (-) IMDM 
to achieve a density of 6.25 $ 106 cells/mL or 6.25 $ 105 cells/mL.  5 $ 106 cells (800 µL) 
or 5 $ 105 cells (800 µL) were transferred to 1.5-mL microcentrifuge tubes and combined 
with specified amounts (10 µg or 20 µg) of CCR5-targeted RNPs at room temperature.  2 
M MgCl2 was added to some samples to a final concentration of 25 mM.  
Electroporations were immediately carried out at 320 V and 800 µF using a Gene Pulser 
II electroporation system (Bio-Rad Laboratories, Electroprotocols Bulletin #D035551).  
After electroporation, cells were incubated at either room temperature or 37°C for 15 min 
and transferred to a T-25 flask containing 10 mL of IMDM complete medium.  Cells 
were incubated overnight at 37°C.  Genomic DNA was extracted using the GenElute 
Mammalian Genomic DNA Miniprep Kit (Sigma).  
Genomic DNA was screened for intron integrations by nested PCR amplification 
of the 3’-integration junction.  For the primary PCR, I used the intron-specific primer, 
ltrB 816s, and a CCR5-specific primer, CCR5 +367-+340.  Primary PCR products were 
purified using the QIAquick PCR Purification Kit (Qiagen).  The purified PCR products 
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served as the template for nested PCR using primers, ltrB 890s and CCR5 +156-+140.  
The thermocycle program for the primary PCR was designed for use with Platinum Taq 
DNA Polymerase (Invitrogen) as follows: 94°C for 2 min, followed by 4 cycles of 94°C 
for 10 s, 64°C for 30 s, 68°C for 2 min, 4 cycles of 94°C for 10 s, 61°C for 30 s, 68°C for 
2, 4 cycles of 94°C for 10 s, 58°C for 30 s, 68°C for 2 min and 30 cycles of 94°C for 10 
s, 56.5°C for 30 s, 68°C for 2 min.  The program used for nested PCR with Taq DNA 
Polymerase (New England Biolabs) was as follows: 95°C for 5 min, followed by 30 
cycles of 95°C for 30 sec, 55°C for 30 sec, 72°C for 2 min and final extension for 10 min 
at 72°C.  
4.2.4 CCR5 PUF Design and Construction 
The CCR5 gene-targeting pick-up fragment (PUF) was constructed by cloning 
three separate PCR products into a pUC19 plasmid backbone.  The three PCR fragments 
included the 5’ homology arm corresponding to CCR5 genomic sequence beginning 30 
nucleotides upstream of the CCR5(332s) intron target site, the 3’ homology arm 
corresponding to CCR5 genomic sequence beginning 10 nucleotides downstream of the 
intron insertion site, and the ATG (-) blasticidin open reading frame with a SV40 polyA 
signal sequence.  The 5’ homology arm consisted of a 2.2-kb fragment amplified from 
genomic DNA of HEK293 cells, using primers CCR5 1561-1585 MluI and CCR5 3768-
3744 XbaI.  The 3’ homology arm consisted of a 4.2-kb fragment also amplified from 
HEK293 genomic DNA, using primers CCR5 3803-3828 SalI and CCR5 7991-7970 
MluI.  The blasticidin resistance gene was amplified without the start codon from 
pCMV/Bsd (Invitrogen), using primers XbaI Bsd –ATG and SacI Bsd Dwnstrm polyA 
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signal.  The PCR products were digested with the appropriate restriction enzymes and 
ligated into the pUC19 plasmid backbone pre-digested with SalI and SacI restriction 
enzymes.  The restriction sites engineered into the PCR primers directed the orientation 
of the fragments in the PUF. 
4.2.5 Electroporation and Selection of K562 Cells for RNP-Stimulated PUF 
Integration 
K562 cells were grown in Iscove’s Modified Dulbecco’s Medium (IMDM), as 
previously described.  5x106 cells were transfected by co-electroporation of 12.5 µg, 25 
µg or 50 µg of CCR5-targeted RNP each with 10 µg of CCR5 PUF DNA linearized by 
MluI digestion.  Control experiments included cells that were pulsed in medium alone 
and cells electroporated with 10 µg PUF alone, 25 µg RNP alone or 50 ng of pCMV/BSD 
(Invitrogen).  The transfected cells were incubated for 15 min post-electroporation at 
room temperature and transferred to T-75 flasks containing 30 mL of IMDM without 
blasticidin.  Cells were incubated at 37°C for 48 h.  After the 48-h incubation, all the cell 
samples received IMDM containing blasticidin at a final concentration of 5 µg/mL.  Cells 
were subsequently incubated at 37°C for 48 h.  After 48 h with 5 µg/mL blasticidin, all 
cell samples received 30 mL IMDM containing blasticidin at a final concentration of 10 
µg/mL.  Subsequently, cells remained under constant selection in IMDM containing 10 
µg/mL blasticidin for the next 25 days.  From day 8 to day 29, cells were maintained in 
10 mL of IMDM with 10 µg/mL blasticidin.  On day 29, 5 $ 106 cells each from samples 
4-7 were collected by centrifugation at 300 ( g for 5 min.  The excess medium was 
removed and the cell pellets were stored at -70°C for genomic DNA extraction.  Also on 
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day 29, 2 $ 104 cells from each sample were diluted into 5 mL IMDM containing 10 
µg/mL blasticidin and added to 100 mm culture plates that had been treated with WSC 
(Sigma) and ConA (Sigma), as described (Anderson & Junker 1994).  Cells were grown 
on the surface of the plates for 4 days until colonies of cells were large enough to be 
picked up by 10 µL pipette tip.  5 days post-plating, colonies were picked from plates 
corresponding to each sample 4-7 and transferred to 96-well plates in 250 µL of IMDM 
with 10 µg/mL blasticidin.  Cells were grown in 96-well plates for 4 days and transferred 
to 24 well plates containing IMDM with 10 µg/mL blasticidin.  Cells were grown in 24 
well plates for 4 days and transferred to T-25 flasks containing 5 mL of IMDM with 10 
µg/mL blasticidin.  Cells were grown in T-25 flasks until samples contained at least 2 $ 
107 cells for DNA and RNA extractions.  Cells were harvested by centrifugation 300 ( g 
for 5 min, medium was removed, and the cell pellets were stored at -70°C until DNA and 
RNA extractions were performed. 
4.2.6 PCR Analysis of K562 Cells Treated with CCR5 RNPs and a Linearized 
dsDNA Plasmid PUF  
Genomic DNA was extracted from frozen cell pellets of samples 4-7 and stock 
K562 cells (#8) using the GenElute Mammalian Genomic DNA Miniprep Kit (Sigma) for 
PCR analysis.  Samples 4-7 were considered to contain heterogeneous populations of 
blasticidin-resistant cells because they were collected prior to the panning method of 
selection for isolated colonies, as described above.  To confirm that the blasticidin 
resistance gene was present in each of the samples containing blasticidin-resistant cells, 
PCR was performed using primers, XbaI Bsd –ATG and Blasticidin 1 anti, to amplify the 
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blasticidin ORF sequence.  To rule out contamination between the positive control 
sample 7 and the others, PCR was performed on samples 4-7 to amplify the blasticidin 
gene along with the CMV promoter using primers, MluI CMV 5’ sense and Blasticidin 1 
anti.  To test the quality of the genomic DNA from sample 6 and to confirm the 
detectability of long PCR products, I designed a series of PCR that amplified fragments 
of increasing lengths when using the Blasticidin 1 anti primer with the following CCR5 
primers: CCR5 3639-3660 (503 bp product), CCR5 3117-3136 (1,025 bp product), CCR5 
2548-2570 (1,594 bp product), CCR5 2098-2121 (2,044 bp product), CCR5 1561-1585 
MluI (2581 bp product), CCR5 exon 1 (2,601 bp product corresponding to PUF 
insertion).  To confirm PUF integration, primers were designed upstream of the 5’ 
homology region of the PUF and used with antisense blasticidin-resistance gene-specific 
primers for PCR to detect a 2.6-kb fragment (CCR5 exon 1 and Blasticidin 1 anti) and for 
nested PCR to detect a ~2.5-kb fragment (CCR5 exon 1b and Blasticidin 2 anti).   
RNA was extracted from samples 6 and 7 for RT-PCR using the RNAqueous 
4PCR Kit (Ambion), according to manufacturer’s instructions.  cDNAs were generated 
using the Blasticidin 1 anti primer and the Superscript II RT Kit (Invitrogen).  The 
cDNAs from sample 6 and sample 7 with and without RT were used as templates for 
PCR.  The BsdR ORF was amplified using primers, XbaI BSD –ATG and Blasticidin 2 
anti.  The thermocycle program for all PCR described here was as follows: 95°C for 5 
min, followed by 30 cycles of 95°C for 30 sec, 55°C for 30 sec, 72°C for 2 min and final 
extension for 10 min at 72°C.  
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4.2.7 Southern Blot Analysis of K562 Genomic DNA to Detect PUF Integrations  
Two DNA probes were PCR amplified for the Southern blotting experiments, a 
CCR5-specific probe and a BsdR gene-specific probe.  The CCR5-probe was amplified 
from K562 genomic DNA using primers, CCR5 1267-1290 and CCR5 1510-1487.  The 
BsdR gene probe was amplified from pCMV/Bsd (Invitrogen) plasmid DNA using 
primers, XbaI Bsd –ATG and Blasticidn 2 anti.  The thermocycle program was designed 
for use with Phusion Mastermix as follows: 98°C for 10 sec, followed by 30 cycles of 
98°C for 1 sec, 65°C for 5 sec, 72°C for 15 sec/1 kb and final extension for 1 min at 
72°C.  The PCR products were labeled using the High Prime DNA Labeling Kit (Roche), 
according to manufacturer’s instructions.  Two labeling reactions were performed for 
each probe.  The two reactions were combined and unincorporated nucleotides were 
removed by eluting through Micro Bio-Spin P-30 spin chromatography columns (Bio-
Rad). 
For the Southern blot, genomic DNA was extracted from samples 4-7 and 
untreated K562 cells, as described above.  Two to five µg of genomic DNA was digested 
overnight with restriction enzyme AflII.  The digested genomic DNA was phenol-CIA 
extracted twice and the digestion products were separated on a 1% agarose gel in 1X 
TAE at 100 V for 3 hours.  The gel was stained with ethidium bromide and photographed 
on a UV transilluminator.  The gel was subsequently soaked while slowly shaking in 
Denaturing Buffer for 30 min at room temperature, Neutralizing Buffer for 30 min at 
room temperature, and 2X SSC transfer buffer for 30 min at room temperature.  The gel 
was rinsed with distilled water between each buffer exchange.  
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The DNA was transferred from the gel to a Nylon membrane (Ambion, 
Brightstar) using a homemade transfer apparatus.  The transfer apparatus consisted of a 
glass dish with a glass plate covering most of the dish.  100 mL of 2X SSC was added to 
the dish. The plate was covered with a piece of filter paper folded so the ends touch the 
buffer (2X SSC).  The gel was placed face down on the Whatman wick.  A nitrocellulose 
membrane (Ambion, Brightstar) cut slightly larger than the gel was pre-soaked for 1 min 
in distilled water followed by 2 min in 2X SSC.  The membrane was placed over the gel 
and the edges were covered with parafilm while not covering the wells or any lanes 
containing DNA.  Two pieces of Whatman filter paper were pre-soaked in 2X SSC and 
placed over the parafilm and membrane.   Four pieces of dry Whatman filter paper were 
placed on top and covered with full pack of dry paper towels followed by a 500 g weight 
for compression.  The DNA transferred overnight at room temperature.  The 
nitrocellulose membrane was removed and neutralized in 2X SSC for 5 min.  While 
soaking in just enough 2X SSC to cover the membrane, the DNA was crosslinked to the 
membrane by placing in a Stratalinker on the “auto-crosslink” setting.   
The nitrocellulose membrane with the freshly transferred genomic DNA was 
prepared for hybridization using Rapid-hyb buffer (Amersham), according to 
manufacturer’s recommendations.  The membrane was incubated in 15 mL Rapid-hyb 
Buffer (Amersham) in a closed hybridization tube for 30 min at 65°C while rotating.  The 
probe was heated for 10 min in boiling water bath and added to 20 mL of fresh Hyb 
Buffer at 65°C.  The Hyb Buffer in the hybridization tube was exchanged with the Hyb 
Buffer containing the probe and incubated for 2 h at 65°C.  The membrane was washed 
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once for 20 min in 50 mL of 2X SSC, 0.1% SDS at 25°C, and twice in 50 mL 1X SSC, 
0.1% SDS at 65°C.  The membrane was then wrapped in saran wrap and 
autoradiographed.   
4.2.8 Production of rAAV for Gene Targeting 
rAAV were prepared two different ways.  Either Carlo Rago prepared the virus, 
as previously described (Rago et al. 2007), or I prepared the virus according to a 
modified version of his protocol, as described here.  Both protocols are modified versions 
of the AAV Helper-Free System Instruction Manual (Stratagene).  AAV-293 cells 
(Stratagene) were grown to 70-80% confluency in 5 x 75-cm2 flasks in DMEM 
(Invitrogen) supplemented with 10% FBS (Hyclone) and penicillin-streptomycin 
(Invitrogen).  Cells were washed with HBSS (Invitrogen) and 7.5 mL of Opti-MEM 
(Invitrogen) was added.  50 µg of each plasmid pAAV-CCR5t, pAAV-RC (Stratagene) 
and pHelper (Stratagene) were combined in a 50-mL conical tube.  Opti-MEM reduced-
serum media (Invitrogen) was added to reach a total volume of 9.375 mL.  In a separate 
tube, 375 µL of lipofectamine 2000 (Invitrogen) was diluted in Opti-MEM to a total 
volume of 9.375 mL.  The DNA solution was added dropwise to the lipofectamine 
solution and incubated at room temperature for 15 min.  3.8 mL of the DNA-
lipofectamine mixture was added dropwise to each of the flasks of cells and incubated at 
37°C for 3-4 h.  After the incubation, the Opti-MEM was replaced with DMEM 
(Invitrogen) supplemented with 10% FBS (Hyclone) and penicillin-streptomycin 
(Invitrogen), and the cells were incubated at 37°C for 48 h.  The media was removed 
from the flask and the cells were scraped into 1 mL of PBS (Invitrogen) using a rubber 
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policeman.  The cell suspension was transferred to a 15-mL tube and centrifuged at 1,000 
( g for 5 min.  The cells were resuspended in 3 mL of PBS and transferred to two 
microcentrifuge tubes.  The cells were lysed by three cycles of freezing and thawing to 
release the virus.  Each cycle consisted of 10 min in a dry ice-ethanol bath and 10 min at 
37°C, vortexing after each thaw.  The lysate was clarified by centrifugation at 15,000 ( g 
in an Eppendorf desktop microcentrifuge 10 min at 4°C.  Aliquots of the supernatant 
were stored at -70°C.  
4.2.9 Electroporation and Selection of HCT116 Cells for Group II Intron RNP-
Stimulated rAAV Integration 
 HCT116 cells were grown at 37°C to 60-80% confluency in HyClone McCoy’s 
5A medium in T-25 flasks.  The growth medium was removed and the cells were washed 
with 5 mL of HBSS (Invitrogen).  The HBSS was removed and specified volumes of 
rAAV were added dropwise to the cells.  2.5 mL of HyClone McCoy’s 5A medium was 
added, and the cells were incubated for 2 h at 37°C.  Each flask of cells was subsequently 
treated according to whether or not the cells would receive an electroporation pulse with 
or without the RNP.  Cells receiving neither the pulse nor the RNP received 4 mL of 
growth medium and were incubated for 48 h at 37°C.  Cells receiving the electroporation 
pulse were rinsed with 5 mL of HBSS.  1 mL of trypsin was added to the flask and 
incubated for 5-10 min at room temperature.  4 mL of complete medium was added to the 
trypsinized cells.  The cells were harvested by centrifugation at 300 x g for 5 min.  The 
cell pellet was resuspended in 5 mL of medium without FBS.  The cells were washed 
twice in medium without FBS.  The cells were counted and diluted in medium w/o FBS 
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to a final concentration concentration of 1.25 $ 106 cells/mL.  Specified amounts of RNPs 
were added to 800 µL aliquots of cells and the cells were electroporated under specified 
conditions.  After electroporation, the cells were transferred to a T-25 flask containing 4 
mL medium without FBS.  After 2 h, the medium was exchanged for complete medium 
and incubated for 48 h at 37°C. 
 After 48 h, the cells were harvested from the T-25 flasks by trypsinization and 
resuspended in compete medium containing 400 µg/mL Geneticin (Invitrogen) to a final 
concentration of 1 x 105 cells/mL.  100 µL of the cell suspension for each sample was 
transferred to each well of a 96-well plate.  The plates were sealed in plastic wrap and 
incubated at 37°C for 14-17 days.  After the colonies were selected, 20 µL of trypsin was 
added to wells containing colonies.  Once the cells were released from the surface of the 
plate, they were resuspended in 200 µL of complete medium and transferred into a 
second 96-well plate to consolidate all the colonies in a single plate.  The new plates were 
incubated at 37°C until the cells reached 80% confluency.  Genomic DNA was extracted 
from the 96-well plates using the 96-well Blood Kit (QIAgen), according to 
manufacturer’s instructions.  The purified DNA was stored at 4°C until needed for PCR 
analysis. 
4.2.10 PCR Screening of HCT116 Cells for Site-Specific rAAV Integrations at the 
CCR5 Target Site 
Genomic DNA was extracted colonies of HCT116 cells, as described above.  The 
PCR strategy for screening the colonies was based on the amplification of the region 
upstream of the integration site using a primer designed to anneal 3’ of the homology 
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region for the rAAV targeting vector, -897 CCR5, and a primer designed to anneal within 
the neoR gene, NR Neo Reverse.  10 µL of the genomic DNA was used as the DNA 
template for the PCR.  The thermocycle program for the primary PCR was designed for 
use with Platinum Taq DNA Polymerase (Invitrogen) as follows: 94°C for 2 min, 
followed by 4 cycles of 94°C for 10 s, 68°C for 30 s, 68°C for 2 min, 4 cycles of 94°C for 
10 s, 64°C for 30 s, 68°C for 2, 4 cycles of 94°C for 10 s, 62°C for 30 s, 68°C for 2 min 
and 30 cycles of 94°C for 10 s, 58°C for 30 s, 68°C for 2 min.  The PCR products were 
separated on a 1% agarose gel and targeting efficiencies were based on the presence or 
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